{"content":"<li class=\"n-box-item date-title\" data-end=\"1488257999\" data-start=\"1488171600\" data-txt=\"Sunday, December 22, 2019\">Monday, February 27, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3246945\" data-ts=\"1488237775\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EOG\" target=\"_blank\">EOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246945-eog-resourcesplus-2-after-beating-q4-estimates\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EOG Resources +2% after beating Q4 estimates</a></h4><ul>     <li>EOG&nbsp;Resources (NYSE:<a href='https://seekingalpha.com/symbol/EOG' title='EOG Resources, Inc.'>EOG</a>) <font color='green'>+1.9%</font>&nbsp;AH after posting a much smaller than expected <a href=\"https://seekingalpha.com/news/3246870-eog-resources-beats-0_13-beats-revenue\" target=\"_blank\">Q4 loss</a> and a 33% Y/Y jump in revenues, and guiding for 18% growth in FY 2017 total company crude oil volumes.</li>     <li>EOG sees 2017 capex of $3.7B-$4.1B vs. $2.7 billion in 2016, and expects to complete ~480 net wells compared to 445 net wells in 2016, with flat to lower completed well costs in 2017 as continued efficiencies and service contract expirations are  expected to offset potential cost increases.</li>     <li>EOG says total net proved reserves rose 1.4% in 2016 to 2.14B boe (55% crude oil and condensate, 19% natural gas liquids, 26% natural gas) and it replaced 163% of 2016 production at a $5.22/boe finding and development cost (excluding price revisions).</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246945\" data-linked=\"EOG Resources +2% after beating Q4 estimates\" data-tweet=\"$EOG - EOG Resources +2% after beating Q4 estimates https://seekingalpha.com/news/3246945-eog-resourcesplus-2-after-beating-q4-estimates?source=tweet\" data-url=\"https://seekingalpha.com/news/3246945-eog-resourcesplus-2-after-beating-q4-estimates\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246937\" data-ts=\"1488236005\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOW\" target=\"_blank\">NOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246937-cowen-and-company-reiterates-servicenow-outperform-following-ceo-modification-updated\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cowen and Company reiterates ServiceNow at Outperform following CEO modification [updated]</a></h4><ul><li><a href=\"http://www.streetinsider.com/Analyst+Comments/Cowen+Remains+Bullish+on+ServiceNow+%28NOW%29+Following+New+CEO+Appointment/12597968.html\" target=\"_blank\">Analyst Derrick Wood</a> notes ServiceNow's appointment of John Donahoe to president and CEO (formerly president and CEO of eBay, present chairman of the board at PayPal) indicates positively as the company targets <a href=\"http://fortune.com/2016/01/28/servicenow-salesforce-annual-revenue-1-billion/\" target=\"_blank\">$4B in revenue for 2020</a>.</li><li>Price target maintained at $110. ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow'>NOW</a>) $87.75,&nbsp;<font color='red'>-4.43%&nbsp;</font>(at close).</li><li>Earlier (February 27, 2017): <a href=\"https://seekingalpha.com/news/3246746-servicenow-minus-3_8-percent-amid-disclosure-ceo-change\" target=\"_blank\">ServiceNow -3.8% amid disclosure of CEO change</a></li><li><strong>Update (5:58PM ET)</strong>: Similarly reiterated positively <a href=\"http://www.streetinsider.com/Analyst+Comments/Mizuho+Securities+Reiterates+Buy+Rating+and+%24100+PT+on+ServiceNow+%28NOW%29+Following+New+CEO+Announcement/12596797.html\" target=\"_blank\">at Mizuho Securities</a> (Buy, $100 target).</li></ul><div class=\"tiny-share-widget\" data-id=\"3246937\" data-linked=\"Cowen and Company reiterates ServiceNow at Outperform following CEO modification [updated]\" data-tweet=\"$NOW - Cowen and Company reiterates ServiceNow at Outperform following CEO modification [updated] https://seekingalpha.com/news/3246937-cowen-and-company-reiterates-servicenow-outperform-following-ceo-modification-updated?source=tweet\" data-url=\"https://seekingalpha.com/news/3246937-cowen-and-company-reiterates-servicenow-outperform-following-ceo-modification-updated\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:53 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246933\" data-ts=\"1488235080\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246933-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers:</b> <a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a> <font color='green'>+19.4%</font>. <a href='https://seekingalpha.com/symbol/SBY' title='Silver Bay Realty Trust Corp.'>SBY</a> <font color='green'>+17.2%</font>. <a href='https://seekingalpha.com/symbol/SBGL' title='Sibanye-Stillwater'>SBGL</a> <font color='green'>+8.0%</font>. <a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a> <font color='green'>+5.7%</font>. <a href='https://seekingalpha.com/symbol/AGI' title='Alamos Gold Inc'>AGI</a> <font color='green'>+5.2%</font>.</li><li><b>Top losers:</b> <a href='https://seekingalpha.com/symbol/FRGI' title='Fiesta Restaurant Group, Inc.'>FRGI</a> <font color='red'>-15.2%</font>. <a href='https://seekingalpha.com/symbol/ESND' title='Essendant'>ESND</a> <font color='red'>-14.4%</font>. <a href='https://seekingalpha.com/symbol/THC' title='Tenet Healthcare Corporation'>THC</a> <font color='red'>-13.1%</font>. <a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-10.6%</font>. <a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-8.2%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246933\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$NTRI $SBY $SBGL - After Hours Gainers / Losers https://seekingalpha.com/news/3246933-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3246933-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:38 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246927\" data-ts=\"1488233591\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALB\" target=\"_blank\">ALB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246927-albemarle-beats-0_05-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Albemarle beats by $0.05, beats on revenue</a></h4><ul><li>Albemarle (NYSE:<a href='https://seekingalpha.com/symbol/ALB' title='Albemarle Corporation'>ALB</a>): Q4 EPS of $0.78 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $696.7M (-3.6% Y/Y) <font color='green'>beats by $50.8M</font>.</li><li>Shares <font color='green'>+2.7%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16754907-albemarle-reports-strong-2016-earnings-finish-record-cash-flow-operations'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246927\" data-linked=\"Albemarle beats by $0.05, beats on revenue\" data-tweet=\"$ALB - Albemarle beats by $0.05, beats on revenue https://seekingalpha.com/news/3246927-albemarle-beats-0_05-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246927-albemarle-beats-0_05-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:13 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246921\" data-ts=\"1488232960\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WUBA\" target=\"_blank\">WUBA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246921-58-com-beats-0_12-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">58.com beats by $0.12, beats on revenue</a></h4><ul><li>58.com (NYSE:<a href='https://seekingalpha.com/symbol/WUBA' title='58.com Inc.'>WUBA</a>): Q4 EPS of $0.00 <font color='green'>beats by $0.12</font>.</li><li>Revenue of $306.6M (+20.1% Y/Y) <font color='green'>beats by $4.85M</font>.</li><li>Shares <font color='green'>+3.1%</font> AH.</li><li><a href='https://seekingalpha.com/pr/16754896-58-com-reports-fourth-quarter-fiscal-year-2016-unaudited-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246921\" data-linked=\"58.com beats by $0.12, beats on revenue\" data-tweet=\"$WUBA - 58.com beats by $0.12, beats on revenue https://seekingalpha.com/news/3246921-58-com-beats-0_12-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246921-58-com-beats-0_12-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246917\" data-ts=\"1488232800\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246917-dryshipsplus-20-on-new-dividend-policy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DryShips +20% on new dividend policy</a></h4><ul>     <li>DryShips (NASDAQ:<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a>) <font color='green'>+20.3%</font>&nbsp;AH after announcing a <a href=\"https://seekingalpha.com/pr/16754751-dryships-inc-announces-initiation-regular-quarterly-dividend-policy-declares-first-dividend\" target=\"_blank\">new dividend policy</a> in which it will pay a regular fixed quarterly dividend of $2.5M to shareholders, and possibly pay additional amounts each quarter depending on market conditions and the company's financial performance.</li>     <li>The dividend likely will work out to ~$0.07/share on a quarterly basis.</li>     <li>DRYS had plunged to a new 52-week low during regular trading, <font color='red'>-16.5%</font> on more than double the average daily volume on new specific news.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246917\" data-linked=\"DryShips +20% on new dividend policy\" data-tweet=\"$DRYS - DryShips +20% on new dividend policy https://seekingalpha.com/news/3246917-dryshipsplus-20-on-new-dividend-policy?source=tweet\" data-url=\"https://seekingalpha.com/news/3246917-dryshipsplus-20-on-new-dividend-policy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>43&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246915\" data-ts=\"1488232746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUM\" target=\"_blank\">HUM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246915-humana-inks-accelerated-stock-buyback-program-1_5b-invested-today\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Humana inks accelerated stock buyback program; $1.5B invested today</a></h4><ul><li>Humana (NYSE:<a href='https://seekingalpha.com/symbol/HUM' title='Humana Inc.'>HUM</a>) entered into an accelerated stock repurchase &#40;ASR&#41; <a href=\"https://seekingalpha.com/filing/3431115\" target=\"_blank\">agreement </a>with Goldman Sachs on February 22. The program is part of the $2.25B share repurchase plan that the company announced on February 14.</li><li>Today, it made a $1.5B payment and received 5,833,738 common shares from GS.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246915\" data-linked=\"Humana inks accelerated stock buyback program; $1.5B invested today\" data-tweet=\"$HUM - Humana inks accelerated stock buyback program; $1.5B invested today https://seekingalpha.com/news/3246915-humana-inks-accelerated-stock-buyback-program-1_5b-invested-today?source=tweet\" data-url=\"https://seekingalpha.com/news/3246915-humana-inks-accelerated-stock-buyback-program-1_5b-invested-today\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:59 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246901\" data-ts=\"1488231861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PRGO\" target=\"_blank\">PRGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246901-perrigo-2016-top-line-up-5-non-gaap-eps-down-6-shares-off-10-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Perrigo 2016 top-line up 5%; non-GAAP EPS down 6%; shares off 10% after hours</a></h4><ul><li>Perrigo Company plc (NASDAQ:<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a>) <a href=\"https://seekingalpha.com/pr/16754739-perrigo-company-plc-reports-select-preliminary-unaudited-calendar-year-2016-financial-results\" target=\"_blank\">preliminary 2016 results </a>($M): Sales: $5,634.8 (+5.3%); Loss/share: ($28.85 - 29.00) due goodwill and intangible asset impairment charges of $5.4B; Non-GAAP EPS: $7.10 - 7.25 (-5.5% from midpoint).</li><li>Auditor E&amp;Y is evaluating its historical revenue recognition practices related to Tysabri. Company says no assurance can be given that financial statements for one or more periods will not need restating.</li><li>The 10-K should be filed no later than March 16.</li><li><strong>2017 Guidance</strong>: EPS: $3.39 - 3.74; Non-GAAP EPS: $6.30 - 6.65. Tysabri EPS: $1.03 - 1.09; Non-GAAP Tysabri: $2.12 - 2.18.</li><li>Shares are down&nbsp;<font color='red'>10%</font>&nbsp;after hours on increased volume.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246868-perrigo-sells-tysabri-royalty-stream-2_85b-cfo-departure-soft-2017-guidance-pressures-shares\" target=\"_blank\">Perrigo sells Tysabri royalty stream for up to $2.85B; CFO departure and soft 2017 guidance pressures shares; down 8% after hours</a> (Feb. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246901\" data-linked=\"Perrigo 2016 top-line up 5%; non-GAAP EPS down 6%; shares off 10% after hours\" data-tweet=\"$PRGO - Perrigo 2016 top-line up 5%; non-GAAP EPS down 6%; shares off 10% after hours https://seekingalpha.com/news/3246901-perrigo-2016-top-line-up-5-non-gaap-eps-down-6-shares-off-10-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3246901-perrigo-2016-top-line-up-5-non-gaap-eps-down-6-shares-off-10-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246899\" data-ts=\"1488231773\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTR\" target=\"_blank\">FTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246899-frontier-communicationsminus-5_5-amid-dips-in-customer-base-average-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Frontier Communications -5.5% amid dips in customer base, average revenue</a></h4><ul>   <li>Frontier Communications (<a href='https://seekingalpha.com/symbol/FTR' title='Frontier Communications Corporation'>FTR</a> <font color='red'>-2.4%</font>) is <font color='red'>another 5.5% lower</font> after dipping into the close, following <a href=\"https://seekingalpha.com/news/3246822-frontier-communications-beats-0_01-misses-revenue\" target=\"_blank\">Q4 earnings</a> where it shed customers and average revenue dropped as it missed sales targets.</li>    <li>The board approved a reverse stock split (between 1-for-10 and 1-for-25) and will recommend it to shareholders for approval at the May annual meeting. It will set the final ratio within 90 days after the charter amendment is approved.</li>    <li>It's also amending credit facilities and combining them into a single agreement. That should grant the company more flexibility, it says, as well as upsizing its revolving credit to $850M and extending it from 2018 to 2022.</li>    <li>CEO Dan McCarthy says post-reorg annualized cost synergies should now be $1.6B by mid-2018, up from a previous $1.4B target.</li>    <li>Residential customers dropped to 4.89M from last quarter's 5.03M; yet average monthly revenue per customer fell to $80.33 from $82.34. Churn stayed at 2.08%.</li>    <li>Business customers dropped to 502,000 from 516,000; ARPU dipped there as well, to $665.04 from $668.30. Broadband subscribers fell to 4.27M from 4.36M, and video subscribers dropped to 1.42M from 1.5M.</li>    <li>For the year, adjusted free cash flow was $921M.</li>    <li>For 2017 it's forecasting adjusted free cash flow of $800M-$1B, capex of $1B-$1.25B, and cash taxes of $0 to $50M.</li>    <li><a href=\"https://seekingalpha.com/pr/16754706-frontier-communications-reports-2016-fourth-quarter-full-year-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3246899\" data-linked=\"Frontier Communications -5.5% amid dips in customer base, average revenue\" data-tweet=\"$FTR - Frontier Communications -5.5% amid dips in customer base, average revenue https://seekingalpha.com/news/3246899-frontier-communicationsminus-5_5-amid-dips-in-customer-base-average-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246899-frontier-communicationsminus-5_5-amid-dips-in-customer-base-average-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>37&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246897\" data-ts=\"1488231659\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KND\" target=\"_blank\">KND</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246897-kindred-healthcare-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kindred Healthcare beats by $0.01, beats on revenue</a></h4><ul><li>Kindred Healthcare (NYSE:<a href='https://seekingalpha.com/symbol/KND' title='Kindred Healthcare, Inc.'>KND</a>): Q4 EPS of $0.08 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $1.75B (-1.7% Y/Y) <font color='green'>beats by $20M</font>.</li><li>Shares <font color='green'>+5.8%</font>.</li><li><a href='https://seekingalpha.com/pr/16754838-kindred-healthcare-reports-fourth-quarter-2016-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246897\" data-linked=\"Kindred Healthcare beats by $0.01, beats on revenue\" data-tweet=\"$KND - Kindred Healthcare beats by $0.01, beats on revenue https://seekingalpha.com/news/3246897-kindred-healthcare-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246897-kindred-healthcare-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246895\" data-ts=\"1488231528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MHLD\" target=\"_blank\">MHLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246895-maiden-holdings-beats-0_17-misses-on-net-premiums-earned\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maiden Holdings beats by $0.17, misses on net premiums earned</a></h4><ul><li>Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>): Q4 EPS of -$0.81 <font color='green'>beats by $0.17</font>.</li><li>net premiums earned of $616.3M (+5.6% Y/Y) <font color='red'>misses by $13.55M</font>.</li><li>Shares <font color='green'>+2.7%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16742530-maiden-holdings-announces-fourth-quarter-2016-loss-reserve-strengthening-primarily-focused\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246895\" data-linked=\"Maiden Holdings beats by $0.17, misses on net premiums earned\" data-tweet=\"$MHLD - Maiden Holdings beats by $0.17, misses on net premiums earned https://seekingalpha.com/news/3246895-maiden-holdings-beats-0_17-misses-on-net-premiums-earned?source=tweet\" data-url=\"https://seekingalpha.com/news/3246895-maiden-holdings-beats-0_17-misses-on-net-premiums-earned\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:38 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246890\" data-ts=\"1488231414\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/X\" target=\"_blank\">X</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246890-u-s-steelplus-3-following-after-hours-upgrade-from-cowen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. Steel +3% following after-hours upgrade from Cowen</a></h4><ul><li>U.S. Steel (NYSE:<a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a>)&nbsp;<font color='green'>+3.2%</font>&nbsp;AH after Cowen issues a late <a href=\"https://twitter.com/thenotablecalls/status/836323808483082241\" target=\"_blank\">upgrade</a> to Outperform from Market Perform with a Street-high $60 price target, up substantially from a prior $36 outlook.</li><li>The stock already jumped 3.2% in today's trade after Pres. Trump promised a \"<a href=\"https://seekingalpha.com/news/3246739-trump-promises-big-statement-infrastructure-spending\" target=\"_blank\">big statement</a>\" on infrastructure spending during tomorrow's address to Congress.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246890\" data-linked=\"U.S. Steel +3% following after-hours upgrade from Cowen\" data-tweet=\"$X - U.S. Steel +3% following after-hours upgrade from Cowen https://seekingalpha.com/news/3246890-u-s-steelplus-3-following-after-hours-upgrade-from-cowen?source=tweet\" data-url=\"https://seekingalpha.com/news/3246890-u-s-steelplus-3-following-after-hours-upgrade-from-cowen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246878\" data-ts=\"1488231072\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246878-workdayminus-2_55-after-hours-despite-better-expected-q4-2017-results-fy-2018-revenue-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday -2.55% after hours despite better-than-expected Q4 2017 results, FY 2018 revenue outlook</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/news/3246824-workday-beats-0_08-beats-revenue\" target=\"_blank\">Q4 2017 results</a></strong> &ndash; revenue $436.67M (+35% Y/Y,&nbsp;<font color='green'>$6.37M above estimates</font>), EPS $0.07 (<font color='green'>$0.08 above estimates</font>), Subscription revenue $365.2M (+39% Y/Y), operating profit $8M (vs. $0.8M operating loss Y/Y)</li><li><strong>Other developments</strong> &ndash; Workday Human Capital Management <a href=\"https://seekingalpha.com/pr/16754715-bp-selects-workday-support-global-hr-modernisation\" target=\"_blank\">selected to replace</a> BP's legacy on-premise HR system.</li><li><strong>FY 2018 projections</strong> &ndash; revenue $2.005B-$2.025B (+27%-29%; <a href=\"https://finance.yahoo.com/quote/WDAY/analysts?p=WDAY\" target=\"_blank\">consensus $1.99B</a>)</li><li>Workday co-founder and CEO Aneel Bhusri: \"In Q4, we delivered the best quarter in company history to close out a very successful fiscal 2017. Our strong performance was driven by a combination of our industry-leading products and technology, continued high levels of customer satisfaction, and our dedicated Workday team. We believe these are the right areas of focus to achieve another great year for Workday in the year ahead.\"</li><li><strong>After hours</strong> &ndash; (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) $87.89.</li><li><a href=\"https://seekingalpha.com/pr/16754716-workday-announces-fourth-quarter-full-year-fiscal-2017-financial-results\" target=\"_blank\">Press release</a> / <a href=\"https://edge.media-server.com/m/p/vb9bo3j9\" target=\"_blank\">conference call</a>&nbsp;/ <a href=\"https://seekingalpha.com/filing/3430769\" target=\"_blank\">8-K</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246878\" data-linked=\"Workday -2.55% after hours despite better-than-expected Q4 2017 results, FY 2018 revenue outlook\" data-tweet=\"$WDAY - Workday -2.55% after hours despite better-than-expected Q4 2017 results, FY 2018 revenue outlook https://seekingalpha.com/news/3246878-workdayminus-2_55-after-hours-despite-better-expected-q4-2017-results-fy-2018-revenue-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3246878-workdayminus-2_55-after-hours-despite-better-expected-q4-2017-results-fy-2018-revenue-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246877\" data-ts=\"1488231033\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SQ\" target=\"_blank\">SQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246877-squareminus-1_7-on-convertible-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Square -1.7% on convertible offering</a></h4><ul><li>The company <a href=\"https://seekingalpha.com/pr/16754690-square-inc-announces-350-million-convertible-notes-offering\" target=\"_blank\">intends to sell </a>$350M in 5-year convertible notes, with initial buyers granted an option to purchase up to another $52.5M of the paper.</li><li><a href='https://seekingalpha.com/symbol/SQ' title='Square, Inc.'>SQ</a>&nbsp;<font color='red'>-1.7%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3246877\" data-linked=\"Square -1.7% on convertible offering\" data-tweet=\"$SQ - Square -1.7% on convertible offering https://seekingalpha.com/news/3246877-squareminus-1_7-on-convertible-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3246877-squareminus-1_7-on-convertible-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:30 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246861\" data-ts=\"1488230406\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKNG\" target=\"_blank\">BKNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246861-dazzling-growth-numbers-from-priceline\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dazzling growth numbers from Priceline</a></h4><ul>     <li>Priceline (PCLN) reports profit increased 21% Y/Y in Q4 to $2.3B.</li><li>Q4 EBITDA of $869M vs. $818M consensus estimate and the company's forecast of $755M to $795M.</li>      <li>Total gross bookings were up 26% to $15.112B. Merchant bookings increased 28% during the quarter.</li>       <li><a href=\"http://files.shareholder.com/downloads/PCLN/3979378203x0x930186/174BE39C-0896-4C7D-AE5F-365D43855DCB/PCLN_Group_Earnings_Release_Q416.pdf\" target=\"_blank\">Priceline earnings release</a> (.pdf)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246828-priceline-beats-1_23-beats-revenue\" target=\"_blank\">Priceline beats by $1.23, beats on revenue</a> (Feb. 27)</li>          <li>PCLN <font color='green'>+1.78%</font> AH to $1661.00.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246861\" data-linked=\"Dazzling growth numbers from Priceline\" data-tweet=\"$BKNG - Dazzling growth numbers from Priceline https://seekingalpha.com/news/3246861-dazzling-growth-numbers-from-priceline?source=tweet\" data-url=\"https://seekingalpha.com/news/3246861-dazzling-growth-numbers-from-priceline\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246854\" data-ts=\"1488230237\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/I\" target=\"_blank\">I</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246854-intelsatplus-25-on-reports-softbank-wants-to-merge-oneweb\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intelsat +25% on reports SoftBank wants to merge it, OneWeb</a></h4><ul>   <li>Intelsat (NYSE:<a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a>) vaulted into a news-pending halt, <font color='green'>up 25%</font>, on word from Sky News that SoftBank (<a href='https://seekingalpha.com/symbol/SFTBY' title='SoftBank Group ADR'>OTCPK:SFTBY</a> <font color='red'>-1.7%</font>) is in advanced talks to combine Intelsat with OneWeb.</li>    <li>That would create a satellite business with an enterprise value of about $18B, and SoftBank would commit to reducing some of Intelsat's debt -- which amounts to about $15.4B at last report.</li>    <li>The companies aren't commenting, but a deal could be outlined alongside Intelsat's earnings report tomorrow if it goes through, Sky News says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246854\" data-linked=\"Intelsat +25% on reports SoftBank wants to merge it, OneWeb\" data-tweet=\"$I $I $SFTBY - Intelsat +25% on reports SoftBank wants to merge it, OneWeb https://seekingalpha.com/news/3246854-intelsatplus-25-on-reports-softbank-wants-to-merge-oneweb?source=tweet\" data-url=\"https://seekingalpha.com/news/3246854-intelsatplus-25-on-reports-softbank-wants-to-merge-oneweb\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>39&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246852\" data-ts=\"1488230174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NTRI\" target=\"_blank\">NTRI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246852-nutrisystem-beats-0_07-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutrisystem beats by $0.07, beats on revenue</a></h4><ul><li>Nutrisystem (NASDAQ:<a href='https://seekingalpha.com/symbol/NTRI' title='Nutrisystem Inc'>NTRI</a>): Q4 EPS of $0.29 <font color='green'>beats by $0.07</font>.</li><li>Revenue of $108.95M (+20.7% Y/Y) <font color='green'>beats by $8.75M</font>.</li><li>Shares <font color='green'>+14.81%</font>.</li><li><a href='https://seekingalpha.com/pr/16754738-nutrisystem-announces-fourth-quarter-full-year-2016-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246852\" data-linked=\"Nutrisystem beats by $0.07, beats on revenue\" data-tweet=\"$NTRI - Nutrisystem beats by $0.07, beats on revenue https://seekingalpha.com/news/3246852-nutrisystem-beats-0_07-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246852-nutrisystem-beats-0_07-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246841\" data-ts=\"1488229922\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBY\" target=\"_blank\">SBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246841-silver-bay-sold-to-tricon-capital-up-20-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silver Bay sold to Tricon Capital; up 20% after hours</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16754769-silver-bay-realty-trust-corp-announces-agreement-acquired-tricon-capital-group-inc-1_4\" target=\"_blank\">The all-cash deal</a> works out to $21.50 per share vs. today's close of $18.17. Shares are<font color='green'> higher by 20%&nbsp;</font>after hours to $21.79. The deal puts a $1.4B enterprise value on Silver Bay (NYSE:<a href='https://seekingalpha.com/symbol/SBY' title='Silver Bay Realty Trust Corp.'>SBY</a>).</li><li>The sale is expected to close in Q2.</li><li>The announcement came alongside Q4 results. Tomorrow's conference call has been cancelled.</li><li>Tricon Capital trades in Toronto and on the OTC here under (<a href='https://seekingalpha.com/symbol/TCNGF' title='Tricon Cap Group Inc'>OTC:TCNGF</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3246841\" data-linked=\"Silver Bay sold to Tricon Capital; up 20% after hours\" data-tweet=\"$SBY $SBY $TCNGF - Silver Bay sold to Tricon Capital; up 20% after hours https://seekingalpha.com/news/3246841-silver-bay-sold-to-tricon-capital-up-20-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3246841-silver-bay-sold-to-tricon-capital-up-20-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246835\" data-ts=\"1488229783\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SBY\" target=\"_blank\">SBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246835-silver-bay-realty-beats-0_02-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Silver Bay Realty beats by $0.02, misses on revenue</a></h4><ul><li>Silver Bay Realty (NYSE:<a href='https://seekingalpha.com/symbol/SBY' title='Silver Bay Realty Trust Corp.'>SBY</a>): Q4 FFO of $0.24 <font color='green'>beats by $0.02</font>.</li><li>Revenue of $32.45M (+5.9% Y/Y) <font color='red'>misses by $0.1M</font>.</li><li>Shares <font color='green'>+18.2%</font>.</li><li><a href=\"https://seekingalpha.com/pr/16754769-silver-bay-realty-trust-corp-announces-agreement-acquired-tricon-capital-group-inc-1_4\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246835\" data-linked=\"Silver Bay Realty beats by $0.02, misses on revenue\" data-tweet=\"$SBY - Silver Bay Realty beats by $0.02, misses on revenue https://seekingalpha.com/news/3246835-silver-bay-realty-beats-0_02-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246835-silver-bay-realty-beats-0_02-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:09 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246828\" data-ts=\"1488229644\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKNG\" target=\"_blank\">BKNG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246828-priceline-beats-1_23-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Priceline beats by $1.23, beats on revenue</a></h4><ul><li>Priceline (PCLN): Q4 EPS of $14.21 <font color='green'>beats by $1.23</font>.</li><li>Revenue of $2.35B (+17.5% Y/Y) <font color='green'>beats by $30M</font>.</li><li>Shares <font color='green'>+3.55%</font>.</li><li><a href='http://investor.shareholder.com/common/download/download.cfm?companyid=PCLN&fileid=930186&filekey=174be39c-0896-4c7d-ae5f-365d43855dcb&filename=PCLN_Group_Earnings_Release_Q416.pdf'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246828\" data-linked=\"Priceline beats by $1.23, beats on revenue\" data-tweet=\"$BKNG - Priceline beats by $1.23, beats on revenue https://seekingalpha.com/news/3246828-priceline-beats-1_23-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246828-priceline-beats-1_23-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:07 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246826\" data-ts=\"1488229570\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXEL\" target=\"_blank\">EXEL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246826-exelixis-beats-0_13-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exelixis beats by $0.13, beats on revenue</a></h4><ul><li>Exelixis (NASDAQ:<a href='https://seekingalpha.com/symbol/EXEL' title='Exelixis, Inc.'>EXEL</a>): Q4 EPS of $0.12 <font color='green'>beats by $0.13</font>.</li><li>Revenue of $77.6M (+680.7% Y/Y) <font color='green'>beats by $11.1M</font>.</li><li>Shares <font color='green'>+3.7%</font>.</li><li><a href='https://seekingalpha.com/pr/16754729-exelixis-announces-fourth-quarter-full-year-2016-financial-results-provides-corporate-update'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246826\" data-linked=\"Exelixis beats by $0.13, beats on revenue\" data-tweet=\"$EXEL - Exelixis beats by $0.13, beats on revenue https://seekingalpha.com/news/3246826-exelixis-beats-0_13-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246826-exelixis-beats-0_13-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>54&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246824\" data-ts=\"1488229531\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246824-workday-beats-0_08-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday beats by $0.08, beats on revenue</a></h4><ul><li>Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>): Q4 EPS of $0.07 <font color='green'>beats by $0.08</font>.</li><li>Revenue of $436.67M (+35.0% Y/Y) <font color='green'>beats by $6.37M</font>.</li><li>Shares <font color='green'>+1.52%</font>.</li><li><a href='https://seekingalpha.com/pr/16754716-workday-announces-fourth-quarter-full-year-fiscal-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246824\" data-linked=\"Workday beats by $0.08, beats on revenue\" data-tweet=\"$WDAY - Workday beats by $0.08, beats on revenue https://seekingalpha.com/news/3246824-workday-beats-0_08-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3246824-workday-beats-0_08-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:05 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246816\" data-ts=\"1488229424\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246816-jefferies-boosts-price-target-on-la-jolla-to-40-after-positive-late-stage-study-of-ljpcminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jefferies boosts price target on La Jolla to $40 after positive late-stage study of LJPC-501</a></h4><ul><li>Stoked by the successful ATHOS-3 study, Jefferies analyst Eun Yang raises her price target on La Jolla Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+76.6%</font>) to $40 (14% upside) from $27 (the current price is $35 so some sort of revision was necessary). She maintains her Buy rating on the stock.</li><li>Earlier today, SunTrust Banks reiterated its Buy rating and raised the price target to $57 (63% upside).</li><li>Chardan Capital rates it a \"Top Pick\" with a $75 (114% upside) price target.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3246816\" data-linked=\"Jefferies boosts price target on La Jolla to $40 after positive late-stage study of LJPC-501\" data-tweet=\"$LJPC - Jefferies boosts price target on La Jolla to $40 after positive late-stage study of LJPC-501 https://seekingalpha.com/news/3246816-jefferies-boosts-price-target-on-la-jolla-to-40-after-positive-late-stage-study-of-ljpcminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3246816-jefferies-boosts-price-target-on-la-jolla-to-40-after-positive-late-stage-study-of-ljpcminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246814\" data-ts=\"1488228920\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BAS\" target=\"_blank\">BAS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246814-basic-energy-adds-74k-hhp-of-pressure-pumping-equipment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Basic Energy adds 74K hhp of pressure pumping equipment</a></h4><ul><li>Basic Energy Services (<a href='https://seekingalpha.com/symbol/BAS' title='Basic Energy Services, Inc.'>BAS</a> <font color='green'>+6.1%</font>) maintains strong gains following news that it <a href=\"https://seekingalpha.com/pr/16753663-basic-energy-services-adds-74000-hydraulic-horsepower-pressure-pumping-equipment\" target=\"_blank\">signed a $28.5M purchase agreement</a> for a 74K horsepower hydraulic pump to be used in two frac spreads beginning in May.</li><li>BAS says the purchase will bring its total frac hhp to 431,650 and  total hhp to 517,445.</li><li>CEO Roe Patterson says BAS has seen an increase in frac activity in its Permian Basin and   Mid-Continent operating areas and expects to have all remaining  stacked  fleet activated by the end of March, and has improved its frac pricing by 5%-15% YTD.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246814\" data-linked=\"Basic Energy adds 74K hhp of pressure pumping equipment\" data-tweet=\"$BAS - Basic Energy adds 74K hhp of pressure pumping equipment https://seekingalpha.com/news/3246814-basic-energy-adds-74k-hhp-of-pressure-pumping-equipment?source=tweet\" data-url=\"https://seekingalpha.com/news/3246814-basic-energy-adds-74k-hhp-of-pressure-pumping-equipment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:55 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246812\" data-ts=\"1488228668\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ATRA\" target=\"_blank\">ATRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246812-biotechs-scorching-today-ibb-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biotechs scorching today, IBB up 3%</a></h4><ul><li>Biotech investors are breaking out the champagne today as the sector enjoys its best day in a month. The iShares Nasdaq Biotechnology ETF (<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='green'>+2.8%</font>) is up on increased volume as it approaches 300, a level last touched in September 2016.</li><li>Healthcare movers (some buoyed by specific news): (<a href='https://seekingalpha.com/symbol/ATRA' title='Atara Biotherapeutics'>ATRA</a> <font color='green'>+15.6%</font>)(<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+79.1%</font>)(<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+156.9%</font>)(<a href='https://seekingalpha.com/symbol/GILD' title='Gilead Sciences, Inc.'>GILD</a> <font color='green'>+0.7%</font>)(<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a> <font color='green'>+0.8%</font>)(<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='green'>+2%</font>)(<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a> <font color='green'>+3.1%</font>)(<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='green'>+0.3%</font>)(<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='green'>+0.5%</font>)(<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+2.6%</font>)(<a href='https://seekingalpha.com/symbol/REGN' title='Regeneron Pharmaceuticals, Inc.'>REGN</a> <font color='green'>+3.1%</font>)(<a href='https://seekingalpha.com/symbol/ACOR' title='Acorda Therapeutics, Inc.'>ACOR</a> <font color='green'>+10.6%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246812\" data-linked=\"Biotechs scorching today, IBB up 3%\" data-tweet=\"$ATRA $IBB $ATRA - Biotechs scorching today, IBB up 3% https://seekingalpha.com/news/3246812-biotechs-scorching-today-ibb-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3246812-biotechs-scorching-today-ibb-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:51 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246805\" data-ts=\"1488226925\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SUN\" target=\"_blank\">SUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246805-sunoco-downgraded-fbr-on-expected-de-leveraging-scenario\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sunoco downgraded at FBR on expected de-leveraging scenario</a></h4><ul>     <li>Sunoco LP&nbsp;(<a href='https://seekingalpha.com/symbol/SUN' title='Sunoco LP'>SUN</a> <font color='red'>-4.2%</font>) is <a href=\"http://www.streetinsider.com/Downgrades/FBR+Capital+Downgrades+Sunoco+%28SUN%29+to+Market+Perform/12595069.html\" target=\"_blank\">downgraded</a> to Market Perform from Outperform with a $28 price target, trimmed from $32, at FBR, after <a href=\"https://seekingalpha.com/news/3245580-sunoco-lp-eps-6_32\" target=\"_blank\">Q4 earnings</a> fell short of expectations, reducing the firm's forecasts for EBITDA and increasing leverage.</li><li>FBR says it continues to believe SUN has multiple options available for reducing leverage, but most options strain cash  flows, and sustaining distribution coverage for the longer term has become a greater concern.</li><li>The firm says its previous expectations of preferred equity and an IDR waiver remain helpful in reducing leverage, but with tempered cash flow forecasts, distribution coverage remains an issue once IDRs are reinstated.</li><li>The firm continues to believe sponsor Energy Transfer Equity (ETE <font color='green'>+0.4%</font>) will protect SUN's cash flows, perhaps even via a takeout scenario similar to Plains All American and Plains GP.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246805\" data-linked=\"Sunoco downgraded at FBR on expected de-leveraging scenario\" data-tweet=\"$SUN $SUN $ET - Sunoco downgraded at FBR on expected de-leveraging scenario https://seekingalpha.com/news/3246805-sunoco-downgraded-fbr-on-expected-de-leveraging-scenario?source=tweet\" data-url=\"https://seekingalpha.com/news/3246805-sunoco-downgraded-fbr-on-expected-de-leveraging-scenario\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>87&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246754\" data-ts=\"1488226502\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRAY\" target=\"_blank\">VRAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246754-fda-clears-viewrays-next-gen-radiation-therapy-system-shares-up-26\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA clears ViewRay&#39;s next-gen radiation therapy system; shares up 26%</a></h4><ul><li>Thinly traded ViewRay (<a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+26.1%</font>) is up on a healthy 26x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16754442-viewray-receives-fda-510-k-clearance-mridian-linac\" target=\"_blank\">announcement </a>that the FDA has granted 510(k) clearance for its MRIdian Linac, its next-generation linear accelerator-based MRI-guided radiation therapy system.</li><li>The first two installations are slated for Henry Ford Hospital in Detroit and Barnes-Jewish Hospital at Washington University in St. Louis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246754\" data-linked=\"FDA clears ViewRay&#39;s next-gen radiation therapy system; shares up 26%\" data-tweet=\"$VRAY - FDA clears ViewRay&#39;s next-gen radiation therapy system; shares up 26% https://seekingalpha.com/news/3246754-fda-clears-viewrays-next-gen-radiation-therapy-system-shares-up-26?source=tweet\" data-url=\"https://seekingalpha.com/news/3246754-fda-clears-viewrays-next-gen-radiation-therapy-system-shares-up-26\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246801\" data-ts=\"1488226205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UA\" target=\"_blank\">UA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246801-nomura-cites-margin-risk-under-armour\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nomura cites margin risk at Under Armour</a></h4><ul> <li>Nomura lowers Under Armour (<a href='https://seekingalpha.com/symbol/UA' title='Under Armour, Inc. Class C'>UA</a>, <a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) to a Reduce rating from Hold on concerns that the high-growth quarters from the company are in the rear-view mirror.</li> <li>Under Armour also faces some margin risk due to a higher mix of low-margin footwear sales, warns the Japanese firm.</li> <li>UA <font color='red'>-2.82%</font>. UAA <font color='red'>-1.47%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246801\" data-linked=\"Nomura cites margin risk at Under Armour\" data-tweet=\"$UA $UA $UAA - Nomura cites margin risk at Under Armour https://seekingalpha.com/news/3246801-nomura-cites-margin-risk-under-armour?source=tweet\" data-url=\"https://seekingalpha.com/news/3246801-nomura-cites-margin-risk-under-armour\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246799\" data-ts=\"1488225739\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246799-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/I' title='Intelsat SA'>I</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/OLED' title='Universal Display Corporation'>OLED</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RNVA' title='Rennova Health, Inc.'>OTCPK:RNVA</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CSPI' title='CSP Inc.'>CSPI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/AXTI' title='AXT Inc'>AXTI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/DWCH' title='Datawatch Corporation'>DWCH</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/HQCL' title='Hanwha Q CELLS Co., Ltd.'>HQCL</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246799\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$GOGO $I $IPDN - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3246799-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3246799-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:02 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246796\" data-ts=\"1488225486\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CCL\" target=\"_blank\">CCL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246796-argus-turns-positive-on-carnival\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Argus turns positive on Carnival</a></h4><ul> <li>Argus upgrades Carnival (<a href='https://seekingalpha.com/symbol/CCL' title='Carnival Corporation'>CCL</a>) to a Buy rating after having the cruise line operator set at Hold.</li> <li>The firm sets a price target of $64 to imply 14% upside potential for shares from current levels.</li> <li>Wall Street <a href=\"https://www.marketbeat.com/stocks/NYSE/CCL/\" target=\"_blank\">ratings scorecard</a> on CCL: 14 Buys, 8 Holds, 1 Sell.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246796\" data-linked=\"Argus turns positive on Carnival\" data-tweet=\"$CCL - Argus turns positive on Carnival https://seekingalpha.com/news/3246796-argus-turns-positive-on-carnival?source=tweet\" data-url=\"https://seekingalpha.com/news/3246796-argus-turns-positive-on-carnival\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246800\" data-ts=\"1488225421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BHP\" target=\"_blank\">BHP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246800-bhp-ceo-says-talks-resumed-strike-hit-escondida-mine\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BHP CEO says talks have resumed at strike-hit Escondida mine</a></h4><ul>     <li>BHP&nbsp;Billiton (<a href='https://seekingalpha.com/symbol/BHP' title='BHP Billiton Limited'>BHP</a> <font color='green'>+1.7%</font>) has r<a href=\"https://www.bloomberg.com/news/articles/2017-02-27/bhp-ceo-says-we-are-back-around-the-table-at-strike-hit-mine\" target=\"_blank\">esumed talks</a> with striking workers at its Escondida copper mine in Chile in an effort to reach a wage agreement, CEO Andrew Mackenzie tells Bloomberg, although the union said yesterday that no discussions were being held.</li>     <li>The CEO says the Escondida workforce already is \"extremely well paid,\" and asks workers to approach issues of productivity and flexibility so the mine can continue to be profitable and provide jobs when ore grades decline in the future.</li>     <li>BHP says the walkout by members of the union representing 2,500 workers - now in its third week - means it is reviewing its guidance for copper output of 1.62M tons in the 12 months to June 30, including 1.07M tons forecast for Escondida.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246800\" data-linked=\"BHP CEO says talks have resumed at strike-hit Escondida mine\" data-tweet=\"$BHP - BHP CEO says talks have resumed at strike-hit Escondida mine https://seekingalpha.com/news/3246800-bhp-ceo-says-talks-resumed-strike-hit-escondida-mine?source=tweet\" data-url=\"https://seekingalpha.com/news/3246800-bhp-ceo-says-talks-resumed-strike-hit-escondida-mine\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:57 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246789\" data-ts=\"1488223218\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246789-transocean-reiterated-sell-bmo-amid-barrons-bump\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Transocean reiterated at Sell by BMO amid Barron&#39;s bump</a></h4><ul>     <li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='green'>+3.7%</font>) enjoys a <a href=\"https://seekingalpha.com/news/3246559-big-upside-transocean-barrons\" target=\"_blank\"><em>Barron's</em> bump</a> after a weekend article said shares could rise more than 35% in the next year or two if oil prices top $60/bbl.</li><li>But BMO analysts are <a href=\"http://blogs.barrons.com/stockstowatchtoday/2017/02/27/transocean-ma-on-the-way/\" target=\"_blank\">reiterating their Sell rating</a> on RIG, saying that despite recent success in cutting costs and improving sales, the company's net asset value still points to shares being worth just $10.</li><li>The firm also contends that &ldquo;M&amp;A may be moving up the agenda,&rdquo; thus increasing the probability of issuing equity to purchase a smaller, distressed competitor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246789\" data-linked=\"Transocean reiterated at Sell by BMO amid Barron&#39;s bump\" data-tweet=\"$RIG - Transocean reiterated at Sell by BMO amid Barron&#39;s bump https://seekingalpha.com/news/3246789-transocean-reiterated-sell-bmo-amid-barrons-bump?source=tweet\" data-url=\"https://seekingalpha.com/news/3246789-transocean-reiterated-sell-bmo-amid-barrons-bump\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246786\" data-ts=\"1488222653\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WTW\" target=\"_blank\">WTW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246786-weight-watchers-gets-perky-ahead-of-resultsplus-5_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Weight Watchers gets perky ahead of results; +5.5%</a></h4><ul><li>The company is expected to report tomorrow after the close. The stock got off to a good start today after M Science <a href=\"https://twitter.com/thenotablecalls/status/836223692816408577\" target=\"_blank\">said Q4 came in</a> just fine, with online signups growing at the fastest pace in three years. It's added noticeably to those gains in the past few minutes.</li><li><a href='https://seekingalpha.com/symbol/WTW' title='Weight Watchers International, Inc.'>WTW</a><font color='green'> +5.5%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3246786\" data-linked=\"Weight Watchers gets perky ahead of results; +5.5%\" data-tweet=\"$WTW $WW - Weight Watchers gets perky ahead of results; +5.5% https://seekingalpha.com/news/3246786-weight-watchers-gets-perky-ahead-of-resultsplus-5_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3246786-weight-watchers-gets-perky-ahead-of-resultsplus-5_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246784\" data-ts=\"1488222045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246784-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/TELL' title='Tellurian Inc.'>TELL</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/IO' title='ION Geophysical Corporation'>IO</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/BCEI' title='Bonanza Creek Energy'>BCEI</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/SNMX' title='Senomyx, Inc.'>SNMX</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/HSC' title='Harsco Corporation'>HSC</a> <font color='green'>+8%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RTK' title='Rentech, Inc'>RTK</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/TRQ' title='Turquoise Hill Resources Ltd.'>TRQ</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/LLEX' title='Lilis Energy, Inc.'>LLEX</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resource Corp'>GSS</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/TGB' title='Taseko Mines Limited'>TGB</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246784\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$TELL $IO $BCEI - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3246784-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3246784-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246781\" data-ts=\"1488221435\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIG\" target=\"_blank\">AIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246781-aig-board-mulling-actions-against-ceo-wsj\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AIG board mulling actions against CEO - WSJ</a></h4><ul><li>Among the items up for debate at an early March board meeting, <a href=\"https://www.wsj.com/articles/aig-directors-to-discuss-whether-to-penalize-or-oust-ceo-over-fourth-quarter-results-1488219815?mod=e2tw\" target=\"_blank\">according to the report</a>, would be cutting CEO Peter Hancock's bonus, or firing him.</li><li>At issue is poor performance at the insurer, including Q4's $3B loss which sent the stock&nbsp;<font color='red'>down 9%</font>&nbsp;in one session earlier this month.</li><li>The news has sent <a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a> from a small loss to&nbsp;<font color='green'>higher by 1.15%&nbsp;</font>on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246781\" data-linked=\"AIG board mulling actions against CEO - WSJ\" data-tweet=\"$AIG - AIG board mulling actions against CEO - WSJ https://seekingalpha.com/news/3246781-aig-board-mulling-actions-against-ceo-wsj?source=tweet\" data-url=\"https://seekingalpha.com/news/3246781-aig-board-mulling-actions-against-ceo-wsj\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246772\" data-ts=\"1488218948\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LB\" target=\"_blank\">LB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246772-victorias-secret-takes-high-priced-bras-to-china\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Victoria&#39;s Secret takes high-priced bras to China</a></h4><ul> <li>The first regular Victoria's Secret store in China <a href=\"http://www.scmp.com/business/companies/article/2073748/victorias-secret-opens-first-flagship-store-china-mainland-women\" target=\"_blank\">opened</a> recently in Shangahi to quite a bit of fanfare.</li> <li>A second store is planned for Chengdu by the end of the year.</li> <li>In an interesting twist, Victoria's Secret plans to take its annual show of lingerie and underwear to Shanghai on the company's view the local market is ready for 600 yuan ($87) bras.</li> <li>Last week, L Brands (<a href='https://seekingalpha.com/symbol/LB' title='L Brands, Inc.'>LB</a> <font color='green'>+2.5%</font>)&nbsp;crumbled off of a weak performance by the Victoria's Secret brand, due in part to a higher mix of lower-margin sports bras and bralettes sales. Shares of LB&nbsp;are up 8.8% from their low point of $47.93.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3245502-weakness-victorias-secret-impacts-l-brands\" target=\"_blank\">Weakness at Victoria's Secret impacts L Brands</a> (Feb. 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3242713-amazon-bra-plan\" target=\"_blank\">Amazon has a bra plan</a> (Feb. 12)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246772\" data-linked=\"Victoria&#39;s Secret takes high-priced bras to China\" data-tweet=\"$LB - Victoria&#39;s Secret takes high-priced bras to China https://seekingalpha.com/news/3246772-victorias-secret-takes-high-priced-bras-to-china?source=tweet\" data-url=\"https://seekingalpha.com/news/3246772-victorias-secret-takes-high-priced-bras-to-china\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246771\" data-ts=\"1488218284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JKS\" target=\"_blank\">JKS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246771-jinko-solarplus-4-after-stronger-expected-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Jinko Solar +4% after stronger than expected Q4</a></h4><ul><li>Jinko Slar (<a href='https://seekingalpha.com/symbol/JKS' title='JinkoSolar Holding Co., Ltd.'>JKS</a> <font color='green'>+4.1%</font>) is higher following a strong <a href=\"https://seekingalpha.com/news/3246601-jinkosolar-holding-beats-0_39-beats-revenue\" target=\"_blank\">Q4 earnings</a> beat, as module shipments rose 7.9% Q/Q and 1.3% Y/Y to 1,733 MW during Q4 and 6,656 MW for FY 2016, making it the world&rsquo;s biggest PV module producer.</li><li>JKS says Q4 revenues fell 21% Y/Y to $737M despite increased shipments but the result still exceeded analyst expectations.</li><li>The company forecasts solar module  shipments of 1.9-2.0 GW for Q1 and 8.5-9.0 GW for FY 2017.</li><li>JKS also says it received &ldquo;<a href=\"https://www.pv-magazine.com/2017/02/27/jinksolar-shipments-grow-in-q4-2016-revenues-margins-fall/\" target=\"_blank\">rush orders</a>&rdquo; from Chinese developers  towards the end of 2016, a trend it expects to continue during H1 2017, and that ASPs in the U.S. have begun to stabilize after a sharp decline during  the quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246771\" data-linked=\"Jinko Solar +4% after stronger than expected Q4\" data-tweet=\"$JKS - Jinko Solar +4% after stronger than expected Q4 https://seekingalpha.com/news/3246771-jinko-solarplus-4-after-stronger-expected-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3246771-jinko-solarplus-4-after-stronger-expected-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246766\" data-ts=\"1488217507\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246766-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+171%</font>. <a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+79%</font>. <a href='https://seekingalpha.com/symbol/BASI' title='Bioanalytical Systems, Inc.'>BASI</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/GRVY' title='GRAVITY Co., Ltd. - American depositary shares, each representing one'>GRVY</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/BID' title='Sotheby&#39;s'>BID</a> <font color='green'>+14%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/GRAM-OLD' title='Graña y Montero'>GRAM-OLD</a> <font color='red'>-27%</font>. ITUS <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/SSTK' title='Shutterstock'>SSTK</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-16%</font>. ARGS <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/CARV' title='Carver Bancorp, Inc.'>CARV</a> <font color='red'>-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246766\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$HTGM $LJPC $BASI - Midday Gainers / Losers https://seekingalpha.com/news/3246766-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3246766-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246761\" data-ts=\"1488215663\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SSL\" target=\"_blank\">SSL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246761-sasol-sees-first-mozambique-oil-production-in-2minus-3-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sasol sees first Mozambique oil production in 2-3 years</a></h4><ul>     <li>Sasol (<a href='https://seekingalpha.com/symbol/SSL' title='Sasol Limited'>SSL</a> <font color='green'>+1.7%</font>) says it has <a href=\"http://www.nasdaq.com/article/update-2sasol-sees-first-mozambique-oil-production-in-23-years-20170227-00374\" target=\"_blank\">found oil in wells off Mozambique</a> and aims to start production there for the first time, co-CEO Stephen Cornell tells Reuters in an interview after the company announced <a href=\"https://seekingalpha.com/news/3246695-sasol-reports-1h-results\" target=\"_blank\">H1 results</a>.</li>     <li>While Mozambique is primarily a gas play, Cornell says SSL has \"drilled four wells, two of them gas, two of them oil, all showing positive results. In one of the areas where we expected mostly gas we found gas and oil.\"</li>     <li>\"This will be the first oil wells in Mozambique that go to full development - probably in two, maximum three years.\" Cornell adds.</li>     <li>SSL says it is scaling back planned capex this year to 66B South African rand (~$5B) from 75B rand in the face of a strengthening rand as it posted a 38% drop in interim earnings, in line with what the company had previously flagged to the market.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246761\" data-linked=\"Sasol sees first Mozambique oil production in 2-3 years\" data-tweet=\"$SSL - Sasol sees first Mozambique oil production in 2-3 years https://seekingalpha.com/news/3246761-sasol-sees-first-mozambique-oil-production-in-2minus-3-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3246761-sasol-sees-first-mozambique-oil-production-in-2minus-3-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:14 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246756\" data-ts=\"1488214810\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246756-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/AMWD' title='American Woodmark Corporation'>AMWD</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/VOXX' title='VOXX International Corp.'>VOXX</a> <font color='green'>+7%</font>.</li>     <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a> <font color='red'>-14%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246756\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$AMWD $VOXX $NVFY - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3246756-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3246756-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246753\" data-ts=\"1488213928\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AES\" target=\"_blank\">AES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246753-aesminus-4-after-big-q4-revenue-miss-below-consensus-2017-eps-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AES -4% after big Q4 revenue miss, below consensus 2017 EPS guidance</a></h4><ul>     <li>AES&nbsp;Corp. (<a href='https://seekingalpha.com/symbol/AES' title='The AES Corporation'>AES</a> <font color='red'>-4.4%</font>) plunges after its <a href=\"https://seekingalpha.com/news/3246605-aes-misses-0_01-misses-revenue\" target=\"_blank\">Q4 earnings</a> results include a sharp revenue miss and below consensus FY 2017 earnings expectations.</li>     <li>AES sees 2017 EPS of $1.00-$1.10 vs. $1.11 analyst consensus estimate, and guides for consolidated free cash flow from operations of $2B-$2.8B with 8%-10% average annual growth, and adjusted EPS through 2020 off the midpoint of its 2016 expectation of $525M-$625M.</li>     <li>AES also says it expects to raise at least $500M in equity proceeds from asset sales in 2017 that will be reallocated in 2017-18.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246753\" data-linked=\"AES -4% after big Q4 revenue miss, below consensus 2017 EPS guidance\" data-tweet=\"$AES - AES -4% after big Q4 revenue miss, below consensus 2017 EPS guidance https://seekingalpha.com/news/3246753-aesminus-4-after-big-q4-revenue-miss-below-consensus-2017-eps-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3246753-aesminus-4-after-big-q4-revenue-miss-below-consensus-2017-eps-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246752\" data-ts=\"1488213818\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVFY\" target=\"_blank\">NVFY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246752-nova-lifestyle-peels-back-after-monster-rally\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nova Lifestyle peels back after monster rally</a></h4><ul> <li>Another bouncy day is in store for Nova Lifestyle (NASDAQ:<a href='https://seekingalpha.com/symbol/NVFY' title='Nova Lifestyle, Inc.'>NVFY</a>) as volume on the stock remains elevated on the online furniture seller.</li> <li>Shares of Nova are currently&nbsp;<font color='red'>down&nbsp;16%</font>&nbsp;to cut into the recent +50% five-day rally tied partially to blockchain news.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3245887-nova-lifestyle-pops-blockchain-news\" target=\"_blank\">Nova Lifestyle pops after blockchain news</a> (Feb. 23)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246752\" data-linked=\"Nova Lifestyle peels back after monster rally\" data-tweet=\"$NVFY - Nova Lifestyle peels back after monster rally https://seekingalpha.com/news/3246752-nova-lifestyle-peels-back-after-monster-rally?source=tweet\" data-url=\"https://seekingalpha.com/news/3246752-nova-lifestyle-peels-back-after-monster-rally\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:43 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246749\" data-ts=\"1488213255\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCX\" target=\"_blank\">FCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246749-shareholders-want-freeport-mcmoran-to-get-tough-indonesia-ceo-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shareholders want Freeport McMoRan to get tough with Indonesia, CEO says</a></h4><ul>     <li><a href=\"http://www.reuters.com/article/mining-bmo-freeport-mcmoran-idUSL2N1GC0KF\" target=\"_blank\">Shareholders are pressuring</a> Freeport McMoRan (<a href='https://seekingalpha.com/symbol/FCX' title='Freeport-McMoRan Inc.'>FCX</a> <font color='green'>+1.9%</font>) to stand up to the Indonesian government over changes the country wants to make in the miner's contract, with many of them believing FCX has \"been too nice,\" CEO&nbsp;Richard Adkerson says.</li>     <li>The CEO says Rio Tinto (<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a> <font color='green'>+1.4%</font>), a partner in FCX's Grasberg copper and gold mine in Indonesia, also supports the company's tougher approach.</li>     <li>In some of his strongest language yet, Adkerson says Indonesia's new regulations are \"in effect a form of expropriation of our assets, and we are resisting it aggressively.\"</li>     <li>FCX remains <a href=\"https://seekingalpha.com/news/3244717-freeport-mcmoran-indonesia-impasse-grasberg-mine\" target=\"_blank\">locked in a standoff</a> with the Indonesian  government over permission to export copper concentrate produced at Grasberg, which accounts for about a third of its annual copper production and 40%-50% of the value of its worldwide assets.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246749\" data-linked=\"Shareholders want Freeport McMoRan to get tough with Indonesia, CEO says\" data-tweet=\"$FCX $FCX $RIO - Shareholders want Freeport McMoRan to get tough with Indonesia, CEO says https://seekingalpha.com/news/3246749-shareholders-want-freeport-mcmoran-to-get-tough-indonesia-ceo-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3246749-shareholders-want-freeport-mcmoran-to-get-tough-indonesia-ceo-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246744\" data-ts=\"1488212166\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HTGM\" target=\"_blank\">HTGM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246744-htg-molecular-to-offer-direct-dna-sequencing-in-march-shares-jump-105\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HTG Molecular to offer direct-DNA sequencing in March; shares jump 105%</a></h4><ul><li>Thinly traded nano cap HTG Molecular Diagnostics (<a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+104.9%</font>) gallops up on a healthy 63x surge in volume (2.6M shares) in response to its <a href=\"https://seekingalpha.com/pr/16753768-htg-molecular-diagnostics-unveils-new-direct-target-sequencing-chemistry-launch-first-quarter\" target=\"_blank\">announcement</a> that it will offer its new direct-target sequencing chemistry as a service starting next month.</li><li>The chemistry is designed for direct sequencing of DNA and, eventually, RNA targets , with the same sensitivity and specificity as its current HTG EdgeSeq chemistry applications.</li><li>The initial panel will detect mutations in the EGFR, KRAS and BRAF genes for retrospective research studies, particularly from small and difficult-to-analyze samples such as formalin-fixed paraffin-embedded tissue.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246744\" data-linked=\"HTG Molecular to offer direct-DNA sequencing in March; shares jump 105%\" data-tweet=\"$HTGM - HTG Molecular to offer direct-DNA sequencing in March; shares jump 105% https://seekingalpha.com/news/3246744-htg-molecular-to-offer-direct-dna-sequencing-in-march-shares-jump-105?source=tweet\" data-url=\"https://seekingalpha.com/news/3246744-htg-molecular-to-offer-direct-dna-sequencing-in-march-shares-jump-105\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:16 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246746\" data-ts=\"1488212006\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NOW\" target=\"_blank\">NOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246746-servicenowminus-3_8-amid-disclosure-of-ceo-change\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ServiceNow -3.8% amid disclosure of CEO change</a></h4><ul><li>Current ServiceNow president, CEO and board chairman Frank Slootman to depart from management April 3, 2017 (will remain board chairman), with John Donahoe (president and CEO of eBay from 2008 to 2015, current PayPal board chairman) to become president and CEO. [<a href=\"https://seekingalpha.com/pr/16754058-servicenow-names-john-donahoe-president-ceo\" target=\"_blank\">press release</a>]</li><li>ServiceNow (NYSE:<a href='https://seekingalpha.com/symbol/NOW' title='ServiceNow'>NOW</a>) $88.30.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246746\" data-linked=\"ServiceNow -3.8% amid disclosure of CEO change\" data-tweet=\"$NOW - ServiceNow -3.8% amid disclosure of CEO change https://seekingalpha.com/news/3246746-servicenowminus-3_8-amid-disclosure-of-ceo-change?source=tweet\" data-url=\"https://seekingalpha.com/news/3246746-servicenowminus-3_8-amid-disclosure-of-ceo-change\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>14&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246743\" data-ts=\"1488211446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VEON\" target=\"_blank\">VEON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246743-vimpelcom-becoming-veonminus-1_6-after-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VimpelCom becoming VEON; -1.6% after revenue miss</a></h4><ul>   <li>After a strong open, VimpelCom (VIP) is <font color='red'>off 1.6%</font> following a miss on revenues in its <a href=\"https://seekingalpha.com/news/3246682-vimpelcom-reports-q4-net-income-1_64b\" target=\"_blank\">Q4 results</a> alongside news that it's rebranding to VEON as it pursues ambitions as a global tech company.</li>    <li>The company is rolling out its <a href=\"https://seekingalpha.com/pr/16753623-vimpelcom-becomes-veon-create-global-tech-company-following-successful-reinvention\" target=\"_blank\">new image</a> (VEON will be the name of the company and its personal Internet platform) at Mobile World Congress in Barcelona this week.</li>    <li>Revenue by region: Russia, $1.1B (up 2.6%); Pakistan, $369M (up 44.4%); Algeria, $246M (down 17.5%); Bangladesh, $152M (down 0.3%); Ukraine, $150M (down 1.4%); Uzbekistan, $165M (down 9.8%); other and eliminations, $150M (down 9.6%).</li>    <li>It will also pursue a second listing on Euronext Amsterdam in Q2, to broaden its European investor base.</li>    <li>It's targeting total organic revenue growth in 2017 of low single digits, as well as underlying equity free cash flow of $700M-$800M (and more than $1B for 2018).</li>    <li><a href=\"https://seekingalpha.com/pr/16753490-vimpelcom-transforms-veon-1-introduces-new-dividend-policy-back-improved-results-robust\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3246743\" data-linked=\"VimpelCom becoming VEON; -1.6% after revenue miss\" data-tweet=\"$VEON - VimpelCom becoming VEON; -1.6% after revenue miss https://seekingalpha.com/news/3246743-vimpelcom-becoming-veonminus-1_6-after-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3246743-vimpelcom-becoming-veonminus-1_6-after-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246742\" data-ts=\"1488211391\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VISN\" target=\"_blank\">VISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246742-visionchinaplus-7_4-reverses-subway-ad-deal-ledman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VisionChina +7.4% as it reverses subway ad deal with Ledman</a></h4><ul>   <li>VisionChina Media (NASDAQ:<a href='https://seekingalpha.com/symbol/VISN' title='VisionChina Media, Inc.'>VISN</a>) is <font color='green'>up 7.4%</font> after saying it's <a href=\"https://seekingalpha.com/pr/16754160-visionchina-media-terminates-transaction-selling-equity-interest-subway-mobile-tv-advertising\" target=\"_blank\">terminating a recently closed sale</a> of nearly half its subway TV ad business, over operating disagreements.</li>    <li>The company had been set for some time to sell a 49% interest in VisionChina New Culture Media, its business operating mobile TV advertising on subways, to Ledman Optoelectronic -- and it closed that deal in September. Last February, it had planned to sell the entire business to Ledman for $119M, but Ledman worked to suspend that deal and it was later terminated.</li>    <li>Now, with disagreements over how to operate New Culture, VisionChina will regain the 49% interest in the business and repay Ledman 61M yuan along with interest, in three installments. It will also repay 321.2M yuan in cash by selling 17.09M shares of Ledman, now pledged as collateral.</li>    <li>\"The company is actively seeking potential purchasers of such equity interest. The company is also exploring other ways to improve its liquidity position,\" it says in a statement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246742\" data-linked=\"VisionChina +7.4% as it reverses subway ad deal with Ledman\" data-tweet=\"$VISN - VisionChina +7.4% as it reverses subway ad deal with Ledman https://seekingalpha.com/news/3246742-visionchinaplus-7_4-reverses-subway-ad-deal-ledman?source=tweet\" data-url=\"https://seekingalpha.com/news/3246742-visionchinaplus-7_4-reverses-subway-ad-deal-ledman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246724\" data-ts=\"1488211222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246724-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/HTGM' title='HTG Molecular Diagnostics'>HTGM</a> <font color='green'>+119%</font>. <a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+77%</font>. <a href='https://seekingalpha.com/symbol/KTOV' title='Kitov Pharma Ltd.'>KTOV</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/IMGN' title='ImmunoGen, Inc.'>IMGN</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/VRAY' title='ViewRay'>VRAY</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/RGLS' title='Regulus Therapeutics'>RGLS</a> <font color='red'>-9%</font>. ARGS <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PULM' title='Pulmatrix, Inc.'>PULM</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MGLN' title='Magellan Health Services, Inc.'>MGLN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/RTTR' title='Ritter Pharmaceuticals'>RTTR</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246724\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$HTGM $LJPC $KTOV - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3246724-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3246724-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246739\" data-ts=\"1488211194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBP\" target=\"_blank\">IBP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246739-trump-promises-big-statement-on-infrastructure-spending\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump promises &quot;big statement&quot; on infrastructure spending</a></h4><ul>     <li><a href=\"http://www.zerohedge.com/news/2017-02-27/risk-bounces-after-trump-promises-start-spending-infrastructure-big-warns-tax-plan\" target=\"_blank\">Infrastructure related stocks bounce</a> after Pres. Trump reiterates he will make a \"big statement\" on his infrastructure plan during Tuesday's address to Congress.</li>     <li>Defense stocks also are on the move on reports that Trump will seek to <a href=\"http://www.reuters.com/article/us-usa-trump-budget-idUSKBN1661R2?il=0\" target=\"_blank\">boost Pentagon spending by $54B</a> in his first budget proposal.</li>     <li>However, Trump also warns that his tax plan would be released only following action on Obamacare.</li>     <li>Among related stocks showing strength: <a href='https://seekingalpha.com/symbol/IBP' title='Installed Building Products, Inc.'>IBP</a> <font color='green'>+8.7%</font>, <a href='https://seekingalpha.com/symbol/MLM' title='Martin Marietta Materials Inc.'>MLM</a> <font color='green'>+3.4%</font>, <a href='https://seekingalpha.com/symbol/URI' title='United Rentals, Inc.'>URI</a> <font color='green'>+3.2%</font>, <a href='https://seekingalpha.com/symbol/VMC' title='Vulcan Materials Company'>VMC</a> <font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/TPC' title='Tutor Perini Corporation'>TPC</a> <font color='green'>+2.6%</font>, <a href='https://seekingalpha.com/symbol/MTW' title='Manitowoc Company, Inc.'>MTW</a> <font color='green'>+2.6%</font>, <a href='https://seekingalpha.com/symbol/ACM' title='AECOM Technology Corporation'>ACM</a> <font color='green'>+2.5%</font>, <a href='https://seekingalpha.com/symbol/TEX' title='Terex Corporation'>TEX</a> <font color='green'>+1.9%</font>, <a href='https://seekingalpha.com/symbol/CAT' title='Caterpillar Inc.'>CAT</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/FLR' title='Fluor Corporation'>FLR</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/MTZ' title='MasTec, Inc.'>MTZ</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/GVA' title='Granite Construction, Inc.'>GVA</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/CX' title='Cemex, S.A.B. de C.V.'>CX</a> <font color='green'>+1.2%</font>, <a href='https://seekingalpha.com/symbol/PWR' title='Quanta Services Inc.'>PWR</a> <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/DE' title='Deere & Company'>DE</a> <font color='green'>+0.8%</font>.</li>     <li>Top defense stocks are broadly higher: <a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a> <font color='green'>+1.7%</font>, <a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color='green'>+1.4%</font>, <a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color='green'>+1.6%</font>, <a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>+0.4%</font>. <a href='https://seekingalpha.com/symbol/LLL' title='L3 Technologies'>LLL</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/TXT' title='Textron Inc'>TXT</a> <font color='green'>+1.3%</font>, <a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1%</font>.</li>     <li>Steel related stocks are rallying: <a href='https://seekingalpha.com/symbol/AKS' title='AK Steel Holding Corp'>AKS</a> <font color='green'>+4.2%</font>, <a href='https://seekingalpha.com/symbol/X' title='United States Steel Corporation'>X</a> <font color='green'>+4%</font>, <a href='https://seekingalpha.com/symbol/ATI' title='Allegheny Technologies Incorporated'>ATI</a> <font color='green'>+3.7%</font>, <a href='https://seekingalpha.com/symbol/CMC' title='Commercial Metals Company'>CMC</a> <font color='green'>+3.7%</font>, <a href='https://seekingalpha.com/symbol/NUE' title='Nucor Corporation'>NUE</a> <font color='green'>+3.4%,</font> <a href='https://seekingalpha.com/symbol/MT' title='ArcelorMittal'>MT</a> <font color='green'>+3.2%</font>, <a href='https://seekingalpha.com/symbol/STLD' title='Steel Dynamics, Inc.'>STLD</a> <font color='green'>+2.7%</font>, <a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+2.2%</font>.</li>     <li>Aluminum names: <a href='https://seekingalpha.com/symbol/KALU' title='Kaiser Aluminum Corporation'>KALU</a> +2.7%, <a href='https://seekingalpha.com/symbol/RS' title='Reliance Steel & Aluminum Co.'>RS</a> <font color='green'>+2.3%</font>, <a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a> <font color='green'>+2%,</font> <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a> <font color='green'>+1.8%</font>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a> <font color='green'>+1.8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246739\" data-linked=\"Trump promises &quot;big statement&quot; on infrastructure spending\" data-tweet=\"$IBP $IBP $MLM - Trump promises &quot;big statement&quot; on infrastructure spending https://seekingalpha.com/news/3246739-trump-promises-big-statement-on-infrastructure-spending?source=tweet\" data-url=\"https://seekingalpha.com/news/3246739-trump-promises-big-statement-on-infrastructure-spending\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>108&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246736\" data-ts=\"1488210904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADXS\" target=\"_blank\">ADXS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246736-advaxis-licenses-lm-based-antigen-delivery-technology-to-sellas-life-sciences-for-up-to-358m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advaxis licenses Lm-based antigen delivery technology to SELLAS Life Sciences for up to $358M; shares ahead 11%</a></h4><ul><li>Advaxis (<a href='https://seekingalpha.com/symbol/ADXS' title='Advaxis Inc.'>ADXS</a> <font color='green'>+11.2%</font>) perks up on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16753845-advaxis-sellas-announce-licensing-agreement-development-wt1-antigen-targeting-immunotherapy\" target=\"_blank\">out-licensing deal</a> with SELLAS Life Sciences Group for its <em>Lm</em>-based antigen delivery technology. SELLAS intends to use it with its WT1-targeted heteroclitic peptide antigen mixture, galinpepimut-S, to develop a novel cancer immunotherapy agent.</li><li>Under the terms of the collaboration, Advaxis will be responsible for all pre-clinical activities to support an IND filing. SELLAS will be responsible for all clinical development and commercialization. Advaxis can earn up to $358M in milestones plus single-digit-to-low-double-digit royalties on net sales.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246736\" data-linked=\"Advaxis licenses Lm-based antigen delivery technology to SELLAS Life Sciences for up to $358M; shares ahead 11%\" data-tweet=\"$ADXS - Advaxis licenses Lm-based antigen delivery technology to SELLAS Life Sciences for up to $358M; shares ahead 11% https://seekingalpha.com/news/3246736-advaxis-licenses-lm-based-antigen-delivery-technology-to-sellas-life-sciences-for-up-to-358m?source=tweet\" data-url=\"https://seekingalpha.com/news/3246736-advaxis-licenses-lm-based-antigen-delivery-technology-to-sellas-life-sciences-for-up-to-358m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246734\" data-ts=\"1488209958\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TRP\" target=\"_blank\">TRP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246734-transcanada-offers-to-sell-stakes-in-two-u-s-pipelines-to-tc-pipelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TransCanada offers to sell stakes in two U.S. pipelines to TC PipeLines</a></h4><ul>     <li>TransCanada (<a href='https://seekingalpha.com/symbol/TRP' title='TransCanada Corporation'>TRP</a> <font color='green'>+0.1%</font>) says it is <a href=\"https://seekingalpha.com/pr/16753819-transcanada-announces-offer-sell-49_3-percent-interest-iroquois-remaining-11_8-percent\" target=\"_blank\">offering to sell</a> its 49.3% interest in the Iroquois  gas transmission system and the remaining 11.8% stake it holds in the Portland natural gas transmission system to its TC&nbsp;PipeLines (<a href='https://seekingalpha.com/symbol/TCP' title='TC PipeLines, LP'>TCP</a> <font color='red'>-2%</font>)&nbsp;MLP.</li>     <li>TCP, whose board still must approve the offer, says the deal would strengthen its cash flows and its ability to increase quarterly distributions this year in line with recent increases.</li>     <li>TRP had sold a 49.9% stake in the Portland pipeline to TCP in January 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246734\" data-linked=\"TransCanada offers to sell stakes in two U.S. pipelines to TC PipeLines\" data-tweet=\"$TRP $TRP $TCP - TransCanada offers to sell stakes in two U.S. pipelines to TC PipeLines https://seekingalpha.com/news/3246734-transcanada-offers-to-sell-stakes-in-two-u-s-pipelines-to-tc-pipelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3246734-transcanada-offers-to-sell-stakes-in-two-u-s-pipelines-to-tc-pipelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246733\" data-ts=\"1488209942\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VISN\" target=\"_blank\">VISN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246733-visionchinaplus-7_4-reverses-subway-ad-deal-ledman\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VisionChina +7.4% as it reverses subway ad deal with Ledman</a></h4><ul>   <li>VisionChina Media (NASDAQ:<a href='https://seekingalpha.com/symbol/VISN' title='VisionChina Media, Inc.'>VISN</a>) is <font color='green'>up 7.4%</font> after saying it's <a href=\"https://seekingalpha.com/pr/16754160-visionchina-media-terminates-transaction-selling-equity-interest-subway-mobile-tv-advertising\" target=\"_blank\">terminating a recently closed sale</a> of nearly half its subway TV ad business, over operating disagreements.</li>    <li>The company had been set for some time to sell a 49% interest in VisionChina New Culture Media, its business operating mobile TV advertising on subways, to Ledman Optoelectronic -- and it closed that deal in September. Last February, it had planned to sell the entire business to Ledman for $119M, but Ledman worked to suspend that deal and it was later terminated.</li>    <li>Now, with disagreements over how to operate New Culture, VisionChina will regain the 49% interest in the business and repay Ledman 61M yuan along with interest, in three installments. It will also repay 321.2M yuan in cash by selling 17.09M shares of Ledman, now pledged as collateral.</li>    <li>\"The company is actively seeking potential purchasers of such equity interest. The company is also exploring other ways to improve its liquidity position,\" it says in a statement.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246733\" data-linked=\"VisionChina +7.4% as it reverses subway ad deal with Ledman\" data-tweet=\"$VISN - VisionChina +7.4% as it reverses subway ad deal with Ledman https://seekingalpha.com/news/3246733-visionchinaplus-7_4-reverses-subway-ad-deal-ledman?source=tweet\" data-url=\"https://seekingalpha.com/news/3246733-visionchinaplus-7_4-reverses-subway-ad-deal-ledman\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246732\" data-ts=\"1488209911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STON\" target=\"_blank\">STON</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246732-stonemorminus-9-on-accounting-issues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">StoneMor -9% on more accounting issues</a></h4><ul><li><a href=\"https://seekingalpha.com/pr/16753723-stonemor-partners-l-p-announces-delay-filing-form-10-k-postponement-investor-conference-call\" target=\"_blank\">The company will delay</a> its 2016 10-K filing and postpone an investor call scheduled for tomorrow morning after the discovery of more accounting issues.</li><li>Revisions are expected to 1) Show a decrease in net deferred revenue, and 2) Increase partners' capital.</li><li>Revisions are not expected to materially impact cash flows for the three years ended Dec. 31, 2016, but they should have a positive impact on future cash flows thanks to additional funds allowed to be withdrawn from merchandise units.</li><li><a href='https://seekingalpha.com/symbol/STON' title='StoneMor Partners L.P.'>STON</a>&nbsp;<font color='red'>-9%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3246732\" data-linked=\"StoneMor -9% on more accounting issues\" data-tweet=\"$STON - StoneMor -9% on more accounting issues https://seekingalpha.com/news/3246732-stonemorminus-9-on-accounting-issues?source=tweet\" data-url=\"https://seekingalpha.com/news/3246732-stonemorminus-9-on-accounting-issues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246726\" data-ts=\"1488209522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246726-la-jollas-angiotensin-ii-successful-in-late-stage-study-shares-ahead-73\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla&#39;s angiotensin II successful in late-stage study; shares ahead 73%</a></h4><ul><li>Thinly traded La Jolla Pharmaceuticals (<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+72.7%</font>) rallies on a whopping 44x surge in volume in response to its <a href=\"https://seekingalpha.com/pr/16753653-la-jolla-pharmaceutical-company-announces-positive-top-line-results-athosminus-3-phase-3\" target=\"_blank\">announcement </a>of positive results from a Phase 3 clinical trial, ATHOS-3, assessing LJPC-501 (angiotensin II) in patients with catecholamine-resistant hypotension &#40;CRH&#41;, an acute life-threatening condition in which blood pressure drops to dangerously low levels despite treatment.</li><li>The study met its primary endpoint of demonstrating a statistically valid percentage of patients achieving a pre-specified target blood pressure response. 70% (n=114/163) of LJPC-501-treated subjects achieved the blood pressure target compared to 23% (n=36/158) for placebo (p&lt;0.00001) with a 22% lower risk of death (hazard ratio = 0.78).</li><li>The company plans to submit a marketing application in the U.S. in H2.</li><li><a href=\"http://lajollapharmaceutical.com/product-pipeline/ljpc-501/\" target=\"_blank\">LJPC-501</a>&nbsp;is a proprietary formulation of&nbsp;<a href=\"http://en.wikipedia.org/wiki/Angiotensin\" target=\"_blank\">angiotensin II</a>, which acts to stabilize blood pressure and help the kidneys balance body fluids and electrolytes.</li><li>Previously: <a href=\"https://seekingalpha.com/news/2388086-la-jolla-pharma-initiates-late-stage-ljpcminus-501-trial\" target=\"_blank\">La Jolla Pharma initiates late stage LJPC-501 trial</a> (March 24, 2015)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246726\" data-linked=\"La Jolla&#39;s angiotensin II successful in late-stage study; shares ahead 73%\" data-tweet=\"$LJPC - La Jolla&#39;s angiotensin II successful in late-stage study; shares ahead 73% https://seekingalpha.com/news/3246726-la-jollas-angiotensin-ii-successful-in-late-stage-study-shares-ahead-73?source=tweet\" data-url=\"https://seekingalpha.com/news/3246726-la-jollas-angiotensin-ii-successful-in-late-stage-study-shares-ahead-73\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246728\" data-ts=\"1488209205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNMA\" target=\"_blank\">FNMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246728-buffett-government-sponsored-mortgages-important-frannie-bad-model\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Buffett: Government sponsored mortgages important; Frannie a bad model</a></h4><ul><li>Appearing on CNBC following this weekend's release of Berkshire Hathaway's annual report, Warren Buffett <a href=\"http://video.cnbc.com/gallery/?video=3000596553&amp;play=1\" target=\"_blank\">calls regularly available</a>, government-guaranteed 30-year mortgages \"enormously important,\" but adds that Fannie Mae (<a href='https://seekingalpha.com/symbol/FNMA' title='Fannie Mae'>OTCQB:FNMA</a> <font color='red'>-4.4%</font>) and Freddie Mac (<a href='https://seekingalpha.com/symbol/FMCC' title='Freddie Mac'>OTCQB:FMCC</a> <font color='red'>-4.3%</font>) are not necessarily needed for this.</li><li>Where we got into trouble, he says, is the private-public partnership of the GSEs. \"Serving two masters [Wall Street and D.C.] is tough,\" says Buffett.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246728\" data-linked=\"Buffett: Government sponsored mortgages important; Frannie a bad model\" data-tweet=\"$FNMA $FNMA $FMCC - Buffett: Government sponsored mortgages important; Frannie a bad model https://seekingalpha.com/news/3246728-buffett-government-sponsored-mortgages-important-frannie-bad-model?source=tweet\" data-url=\"https://seekingalpha.com/news/3246728-buffett-government-sponsored-mortgages-important-frannie-bad-model\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>138&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246727\" data-ts=\"1488209192\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIN\" target=\"_blank\">WIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246727-windstream-closes-merger-earthlink-shares-up-5_2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Windstream closes merger with EarthLink; shares up 5.2%</a></h4><ul>   <li>Windstream Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/WIN' title='Windstream Holdings, Inc.'>WIN</a>) is <font color='green'>up 5.2%</font> after noting it's <a href=\"https://seekingalpha.com/pr/16754123-windstream-completes-merger-earthlink\" target=\"_blank\">wrapped up its merger</a> with EarthLink (NASDAQ:<a href='https://seekingalpha.com/symbol/ELNK' title='EarthLink, Inc.'>ELNK</a>), following Friday's <a href=\"https://seekingalpha.com/news/3246551-windstream-shareholders-approve-merger-earthlink\" target=\"_blank\">shareholder approvals</a>.</li>    <li>The newly combined Windstream will be headquartered in Little Rock, Ark.</li>    <li>The company has also boosted its earlier expectations for synergies, saying it now sees more than $150M in annual operating and capex synergies within 36 months.</li>    <li>Three of EarthLink's directors have been added to Windstream's board effective March 1, bringing the board's total to 12 directors.</li>    <li>Windstream will hold a conference call to discuss the deal and Q4 results at 8:30 a.m. ET on Wednesday.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246727\" data-linked=\"Windstream closes merger with EarthLink; shares up 5.2%\" data-tweet=\"$WIN $WINMQ $ELNK - Windstream closes merger with EarthLink; shares up 5.2% https://seekingalpha.com/news/3246727-windstream-closes-merger-earthlink-shares-up-5_2?source=tweet\" data-url=\"https://seekingalpha.com/news/3246727-windstream-closes-merger-earthlink-shares-up-5_2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246721\" data-ts=\"1488208307\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMPE\" target=\"_blank\">AMPE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246721-ampio-closes-in-bla-submission-for-ampion-for-oak-related-pain-shares-ahead-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ampio closes in BLA submission for Ampion for OAK-related pain; shares ahead 15%</a></h4><ul><li>Thinly traded nano cap Ampio Pharmaceuticals (<a href='https://seekingalpha.com/symbol/AMPE' title='Ampio Pharmaceuticals, Inc.'>AMPE</a> <font color='green'>+15%</font>) perks up on modestly higher volume in response to its <a href=\"https://seekingalpha.com/pr/16753998-ampio-receives-guidance-fda-proposes-path-approval-single-injection-ampion-treatment-pain-due\" target=\"_blank\">announcement </a>of a path to U.S. approval for single-injection Ampion to treat pain due to severe osteoarthritis of the knee &#40;OAK&#41;.</li><li>Based on guidance from the FDA, the company has proposed a small 12-week pre-approval study comparing Ampion to saline that will be conducted in parallel with its preparation for a Biologics License Application &#40;BLA&#41; submission.</li><li>Ampion failed two earlier Phase 3 studies in OAK, one last June and the other in 2015.</li><li><a href=\"http://ampiopharma.com/pipeline/ampion/\" target=\"_blank\">Ampion&nbsp;</a>is a low molecular weight fraction of human serum albumin &#40;HSA&#41;. Its main ingredient is an immunomodulatory molecule derived from HSA called aspartyl-alanyl diketopiperazine (DA-DKP). DA-DKP is believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T cells.</li><li>Management plans to host a conference call in the near future to discuss its corporate strategy and additional indications for Ampion.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246721\" data-linked=\"Ampio closes in BLA submission for Ampion for OAK-related pain; shares ahead 15%\" data-tweet=\"$AMPE - Ampio closes in BLA submission for Ampion for OAK-related pain; shares ahead 15% https://seekingalpha.com/news/3246721-ampio-closes-in-bla-submission-for-ampion-for-oak-related-pain-shares-ahead-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3246721-ampio-closes-in-bla-submission-for-ampion-for-oak-related-pain-shares-ahead-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246711\" data-ts=\"1488207418\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLRB\" target=\"_blank\">CLRB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246711-cellectar-bios-lead-product-candidate-shows-positive-effect-in-early-stage-multiple-myeloma\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cellectar Bio&#39;s lead product candidate shows positive effect in early-stage multiple myeloma study; shares ahead 14%</a></h4><ul><li>Nano cap Cellectar Biosciences (<a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+14%</font>) heads north on average volume in response to its <a href=\"https://seekingalpha.com/pr/16753911-cellectar-biosciences-provides-phase-trial-update-clr-131-multiple-myeloma-median-progression\" target=\"_blank\">announcement </a>of encouraging results from a Phase 1 clinical trial assessing lead product candidate CLR 131 in patients with relapsed/refractory multiple myeloma &#40;MM&#41;.</li><li>All four patients in Cohort 3 (25 mCi/m2) achieved stable disease after a single-dose infusion of CLR 131 with no unexpected adverse events (AEs). The AEs observed were predictable and manageable. They are being followed for progression-free survival &#40;PFS&#41; and median overall survival &#40;OS&#41;.</li><li>Median OS in Cohort 1 (12.5 mCi/m2) is 17.7 months to date while Cohort 2 (18.75 mCi/m2) is 8.4 months. Both are increasing. Median PFS is 92 days and 133 days, respectively. Based on the data, the company has the option of selecting 18.75 mCi/m2 as the optimal dose for future clinical trials.</li><li>CLR 131 is a&nbsp;<a href=\"http://cellectar.com/pdc-platform/\" target=\"_blank\">phospholipid ether-drug conjugate</a>&nbsp;that selectively delivers a cytotoxic payload to cancer cells. The basis for the selectivity is the difference in the plasma membranes of cancer cells compared to normal cells. Cancer cell membranes are highly enriched with regions called lipid rafts which contain high concentrations of cholesterol and&nbsp;<a href=\"https://www.ncbi.nlm.nih.gov/books/NBK1909/\" target=\"_blank\">sphingolipids</a>, a type of fatty acid containing a sugar molecule.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3245284-cellectar-bio-advancing-lead-product-candidate-crl-131-mid-stage-study-multiple-myeloma-start\" target=\"_blank\">Cellectar Bio advancing lead product candidate CRL 131, mid-stage study in multiple myeloma to start this quarter</a> (Feb. 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246711\" data-linked=\"Cellectar Bio&#39;s lead product candidate shows positive effect in early-stage multiple myeloma study; shares ahead 14%\" data-tweet=\"$CLRB - Cellectar Bio&#39;s lead product candidate shows positive effect in early-stage multiple myeloma study; shares ahead 14% https://seekingalpha.com/news/3246711-cellectar-bios-lead-product-candidate-shows-positive-effect-in-early-stage-multiple-myeloma?source=tweet\" data-url=\"https://seekingalpha.com/news/3246711-cellectar-bios-lead-product-candidate-shows-positive-effect-in-early-stage-multiple-myeloma\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246715\" data-ts=\"1488207354\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AFSI\" target=\"_blank\">AFSI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246715-amtrustminus-15-on-after-disclosing-accounting-issues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmTrust -15% on after disclosing accounting issues</a></h4><ul><li>Alongside Q4 results, AmTrust (<a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-15.1%</font>) reports the finding of \"material weaknesses in its internal control over financial reporting that existed as of Dec. 31, 2016.\"</li><li>The company will ask for an extension of time to file its 2016 10-K, and immaterial corrections and errors are expected for previous years.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246613-amtrust-financial-services-eps-0_38\" target=\"_blank\">AmTrust Financial Services EPS of $0.38</a> (Feb. 27)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246715\" data-linked=\"AmTrust -15% on after disclosing accounting issues\" data-tweet=\"$AFSI - AmTrust -15% on after disclosing accounting issues https://seekingalpha.com/news/3246715-amtrustminus-15-on-after-disclosing-accounting-issues?source=tweet\" data-url=\"https://seekingalpha.com/news/3246715-amtrustminus-15-on-after-disclosing-accounting-issues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:55 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>28&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246710\" data-ts=\"1488206677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FCH\" target=\"_blank\">FCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246710-land-and-buildings-ashford-bid-for-felcor-woefully-inadequate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Land and Buildings: Ashford bid for FelCor &quot;woefully inadequate&quot;</a></h4><ul><li>An owner of 6.1% of FelCor Lodging (<a href='https://seekingalpha.com/symbol/FCH' title='FelCor Lodging Trust'>FCH</a> <font color='green'>+1%</font>), Land and Buildings' Jonathan Litt figures the company's <a href=\"https://app.stockboard.com/discover/company/felcor-lodging-trust-inc/release/land-and-buildings-comments-on-ashford%E2%80%99s-offer-to-acquire-felc\" target=\"_blank\">net asset value at $10.50 per share</a> vs. Ashford Trust's (<a href='https://seekingalpha.com/symbol/AHT' title='Ashford Hospitality Trust, Inc.'>AHT</a> <font color='green'>+5%</font>) $9.27 <a href=\"https://seekingalpha.com/news/3244745-ashford-hospitality-goes-hostile-felcor-lodging-fch-plus-11-percent\" target=\"_blank\">all-stock offer.</a></li><li>Litt also takes note of about $640M in cash - or nearly $5 per FelCor share - sitting at Ashford Trust and its manager Ashford Inc. (<a href='https://seekingalpha.com/symbol/AINC' title='Ashford Inc.'>AINC</a>), and wonders why the Ashford bid didn't include a substantial cash component.</li><li>Even more, there's the perpetual management contract the FelCor assets would be encumbered with after the merger, which Litt figures to be likely worth more than $300M, or more than $2 per FelCor share.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246710\" data-linked=\"Land and Buildings: Ashford bid for FelCor &quot;woefully inadequate&quot;\" data-tweet=\"$FCH $FCH $AHT - Land and Buildings: Ashford bid for FelCor &quot;woefully inadequate&quot; https://seekingalpha.com/news/3246710-land-and-buildings-ashford-bid-for-felcor-woefully-inadequate?source=tweet\" data-url=\"https://seekingalpha.com/news/3246710-land-and-buildings-ashford-bid-for-felcor-woefully-inadequate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246699\" data-ts=\"1488205475\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GOGO\" target=\"_blank\">GOGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246699-gogoplus-11_8-after-q4-beat-on-solid-sales-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gogo +11.8% after Q4 beat on solid sales growth</a></h4><ul>   <li>Gogo (NASDAQ:<a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a>) is <font color='green'>up 11.8%</font> premarket after posting <a href=\"https://seekingalpha.com/news/3246638-gogo-beats-0_12-beats-revenue\" target=\"_blank\">Q4 earnings</a> where it beat on top and bottom lines and boosted expectations for 2017 installations.</li>    <li>Revenues grew 16% and its net loss narrowed while EBITDA grew 187% to a record $23.1M.</li>    <li>The company's 2Ku base covers more than 130 aircraft, and Gogo is increasing installation guidance to 450-550 aircraft in 2017, and 650-750 in 2018.</li>    <li>That should help the company to become free cash flow positive in 2019, a year earlier than guided, says CFO Norman Smagley. It's also guiding to 2017 revenue of $670M-$695M (growth of 12-17%, and above consensus for $662M) and EBITDA of $60M-$75M, below an expected $77.9M.</li>    <li>Revenue breakout: Service, $138.9M (up 19.8%); Equipment, $21.1M (down 3.4%).</li>    <li>Total revenue by segment: Commercial Aviation-North America, $101.1M; CA-Rest of World, $7.4M; Business Aviation, $51.5M. Profit by segment: CA-NA, $24.9M; CA-ROW, -$24.7M; BA, $22.98M</li>    <li><a href=\"https://seekingalpha.com/article/4049991-gogo-2016-q4-results-earnings-call-slides\" target=\"_blank\">Earnings slides</a></li>    <li><a href=\"https://seekingalpha.com/pr/16753744-gogo-announces-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3246699\" data-linked=\"Gogo +11.8% after Q4 beat on solid sales growth\" data-tweet=\"$GOGO - Gogo +11.8% after Q4 beat on solid sales growth https://seekingalpha.com/news/3246699-gogoplus-11_8-after-q4-beat-on-solid-sales-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3246699-gogoplus-11_8-after-q4-beat-on-solid-sales-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246698\" data-ts=\"1488205468\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLSD\" target=\"_blank\">CLSD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246698-clearside-bio-backs-off-plans-to-develop-axitinib-for-wet-amd-in-favor-of-dme-lead-candidate\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Clearside Bio backs off plans to develop axitinib for wet AMD in favor of DME with lead candidate Zuprata; shares up 3% premarket</a></h4><ul><li>Thinly traded micro cap Clearside Biomedical (NASDAQ:<a href='https://seekingalpha.com/symbol/CLSD' title='Clearside Biomedical'>CLSD</a>) perks up&nbsp;<font color='green'>3%</font>&nbsp;premarket on light volume in response to its <a href=\"https://seekingalpha.com/pr/16753919-clearside-biomedical-inc-redirects-pre-clinical-amd-research-resources-toward-ongoing-dme\" target=\"_blank\">announcement </a>that it has shelved, for now, its plans to submit an IND for a suspension formulation of axitinib to treatment wet AMD. Its decision was prompted by advances made by other companies developing combination therapies to treat the disorder.</li><li>Management says it will devote more R&amp;D resources to developing Zuprata (triamcinolone acetonide) for diabetic macular edema &#40;DME&#41;. In November, it commenced a Phase 1/2 study assessing Zuprata as monotherapy or in combination with Regeneron's EYLEA (aflibercept) in DME.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246698\" data-linked=\"Clearside Bio backs off plans to develop axitinib for wet AMD in favor of DME with lead candidate Zuprata; shares up 3% premarket\" data-tweet=\"$CLSD - Clearside Bio backs off plans to develop axitinib for wet AMD in favor of DME with lead candidate Zuprata; shares up 3% premarket https://seekingalpha.com/news/3246698-clearside-bio-backs-off-plans-to-develop-axitinib-for-wet-amd-in-favor-of-dme-lead-candidate?source=tweet\" data-url=\"https://seekingalpha.com/news/3246698-clearside-bio-backs-off-plans-to-develop-axitinib-for-wet-amd-in-favor-of-dme-lead-candidate\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246694\" data-ts=\"1488204914\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246694-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/CLRB' title='Cellectar Biosciences, Inc.'>CLRB</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/GOGO' title='Gogo'>GOGO</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/CEMP' title='Cempra, Inc.'>CEMP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/MYSZ' title='MySize Inc.'>MYSZ</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='green'>+6%</font>. VIP <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a> <font color='green'>+5%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/SSTK' title='Shutterstock'>SSTK</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/AFSI' title='AmTrust Financial Services, Inc.'>AFSI</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-10%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246694\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$LJPC $CLRB $PIRS - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3246694-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3246694-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:15 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246693\" data-ts=\"1488204647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RNN\" target=\"_blank\">RNN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246693-rexahn-pharmaceuticals-reports-fy-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rexahn Pharmaceuticals reports FY results</a></h4><ul><li>Rexahn Pharmaceuticals (NYSEMKT:<a href='https://seekingalpha.com/symbol/RNN' title='Rexahn Pharmaceuticals Inc'>RNN</a>): FY EPS of -$0.04</li><li>Shares <font color='green'>+5.04%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/16754186-rexahn-pharmaceuticals-reports-full-year-2016-financial-results-provides-corporate-update\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3246693\" data-linked=\"Rexahn Pharmaceuticals reports FY results\" data-tweet=\"$RNN $REXN - Rexahn Pharmaceuticals reports FY results https://seekingalpha.com/news/3246693-rexahn-pharmaceuticals-reports-fy-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3246693-rexahn-pharmaceuticals-reports-fy-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:10 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246689\" data-ts=\"1488204227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BID\" target=\"_blank\">BID</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246689-sothebys-breaks-higher-after-strong-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sotheby&#39;s breaks higher after strong Q4 results</a></h4><ul> <li>Sotheby's (NYSE:<a href='https://seekingalpha.com/symbol/BID' title='Sotheby&#39;s'>BID</a>) trades higher after flying past estimates with its Q4 report.</li> <li>Net income soared 69% to $74.1M as the company's auction commission margin rate jumped 280 bps to 17.1%. A lower effective tax rate and reduced share count also worked in the favor of EPS.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3246633-sothebys-beats-0_18-beats-revenue\" target=\"_blank\">Sotheby's beats by $0.18, beats on revenue</a> (Feb. 27)</li> <li>BID <font color='green'>+6.39%</font> premarket to $42.65.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246689\" data-linked=\"Sotheby&#39;s breaks higher after strong Q4 results\" data-tweet=\"$BID - Sotheby&#39;s breaks higher after strong Q4 results https://seekingalpha.com/news/3246689-sothebys-breaks-higher-after-strong-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3246689-sothebys-breaks-higher-after-strong-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246687\" data-ts=\"1488203857\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246687-sangamo-nabs-rare-pediatric-disease-tag-for-sbminus-318-for-mps-i-shares-ahead-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo nabs rare pediatric disease tag for SB-318 for MPS I; shares ahead 7% premarket</a></h4><ul><li>Sangamo Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16753933-sangamo-therapeutics-receives-rare-pediatric-disease-designation-fda-sbminus-318-vivo-genome\" target=\"_blank\">announcement </a>that the FDA has granted rare pediatric disease designation for Orphan Drug-tagged SB-318 for the treatment of a lysosomal storage disorder called Mucopolysaccharidosis Type I (MPS I).</li><li>Phase 1/2-stage SB-318 is a zinc finger nuclease &#40;ZFN&#41;&nbsp;gene editing therapy designed to provided stable continuous production of the IDUA enzyme.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity in the U.S. for the indication, if approved, which will also earn the company a Rare Pediatric Disease Priority Review Voucher that can be used for accelerated review of a different product or can be sold or transferred.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246687\" data-linked=\"Sangamo nabs rare pediatric disease tag for SB-318 for MPS I; shares ahead 7% premarket\" data-tweet=\"$SGMO - Sangamo nabs rare pediatric disease tag for SB-318 for MPS I; shares ahead 7% premarket https://seekingalpha.com/news/3246687-sangamo-nabs-rare-pediatric-disease-tag-for-sbminus-318-for-mps-i-shares-ahead-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3246687-sangamo-nabs-rare-pediatric-disease-tag-for-sbminus-318-for-mps-i-shares-ahead-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246684\" data-ts=\"1488203074\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246684-biocryst-reverses-premarket-down-24\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst reverses premarket, down 24%</a></h4><ul><li>The modest premarket bump in BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) after it reported positive interim data on BCX7353 is a distant memory. Shares are now down<font color='red'> 24%</font>&nbsp;on robust volume.</li><li>Troubling safety data is the typical culprit behind this kind of action but the adverse events observed in APeX-1 did not appear to be out of line. Two patients discontinued treatment during the 28-period, one due to an unrelated pre-existing condition and one due to gastroenteritis associated with elevated liver enzymes. The company did not provide any additional data on this patient (e.g., the degree of enzyme elevation, whether it resolved after cessation of treatment, which dose of BCX7353).</li><li>The company also <a href=\"https://seekingalpha.com/pr/16753688-biocryst-reports-fourth-quarter-full-year-2016-financial-results\" target=\"_blank\">reported</a> Q4 and full-year results this morning. Revenue beat consensus by almost $5M. The company says $5.7M of its peramivir royalty revenue in 2016 was due to Japanese government stockpiling so it may not recur on an annual basis.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246684\" data-linked=\"BioCryst reverses premarket, down 24%\" data-tweet=\"$BCRX - BioCryst reverses premarket, down 24% https://seekingalpha.com/news/3246684-biocryst-reverses-premarket-down-24?source=tweet\" data-url=\"https://seekingalpha.com/news/3246684-biocryst-reverses-premarket-down-24\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246669\" data-ts=\"1488201370\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PIRS\" target=\"_blank\">PIRS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246669-pieris-pharma-inks-agreement-in-japan-for-potential-out-license-of-anemia-candidate-prsminus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pieris Pharma inks agreement in Japan for potential out-license of anemia candidate PRS-080; shares ahead 16% premarket</a></h4><ul><li>Thinly traded nano cap Pieris Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/PIRS' title='Pieris Pharmaceuticals, Inc.'>PIRS</a>) is up&nbsp;<font color='green'>16%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16753806-pieris-signs-1st-partnership-anemia-drug-prsminus-080-granting-exclusive-option-japan-aska\" target=\"_blank\">option deal </a>with Japanese firm ASKA Pharmaceutical Co., Ltd. for anemia drug PRS-080 for Japan and certain other Asian markets, its first. ASKA will have the exclusive option to license PRS-080 based on the completion of a Phase 2a study to be conducted by Pieris in dialysis-dependent anemia patients.</li><li>Under the terms of the agreement, Pieris will receive an immediate payment of $2.75M. Following an analysis period after the Phase 2a trial is completed, ASKA may exclusively license the product candidate in Japan, South Korea and certain other Asian markets (excluding China). It if does so, Pieris will be eligible to receive more than $80M in milestones and an option exercise fee related to the first indication in Japan. Pieris can earn additional milestones for additional indications as well as in other countries in ASKA's territory and will earn mid-to-high-teen royalties on net sales.</li><li><a href=\"http://www.pieris.com/pipeline/overview\" target=\"_blank\">PRS-080</a>, a PEGylated Anticalin protein that binds to&nbsp;<a href=\"https://en.wikipedia.org/wiki/Hepcidin\" target=\"_blank\">hepcidin</a>, is a naturally occurring regulator of iron in the blood. It is being developed for the treatment of functional iron deficiency in anemic patients with chronic kidney disease.&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3246669\" data-linked=\"Pieris Pharma inks agreement in Japan for potential out-license of anemia candidate PRS-080; shares ahead 16% premarket\" data-tweet=\"$PIRS - Pieris Pharma inks agreement in Japan for potential out-license of anemia candidate PRS-080; shares ahead 16% premarket https://seekingalpha.com/news/3246669-pieris-pharma-inks-agreement-in-japan-for-potential-out-license-of-anemia-candidate-prsminus?source=tweet\" data-url=\"https://seekingalpha.com/news/3246669-pieris-pharma-inks-agreement-in-japan-for-potential-out-license-of-anemia-candidate-prsminus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246654\" data-ts=\"1488199885\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACRX\" target=\"_blank\">ACRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246654-fda-accepts-acelrxs-nda-for-pain-med-arxminus-04-action-date-october-12-shares-ahead-7\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA accepts AcelRx&#39;s NDA for pain med ARX-04; action date October 12; shares ahead 7% premarket</a></h4><ul><li>Thinly traded micro cap AcelRx Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ACRX' title='AcelRx Pharmaceuticals, Inc.'>ACRX</a>) is up&nbsp;<font color='green'>7%</font>&nbsp;premarket, albeit on only 300 shares, in response to its <a href=\"https://seekingalpha.com/pr/16753753-acelrx-pharmaceuticals-new-drug-application-dsuvia-accepted-filing-pdufa-date-october-12-2017\" target=\"_blank\">announcement </a>that the FDA has accepted for review its New Drug Application &#40;NDA&#41; seeking approval of ARX-04, branded as DSUVIA, for the treatment of moderate-to-severe pain in a medically supervised setting. The agency's action date &#40;PDUFA&#41; is October 12.</li><li><a href=\"http://www.acelrx.com/pipeline/arx-04.html\" target=\"_blank\">ARX-04</a>&nbsp;consists of 30 mcg tablets of&nbsp;<a href=\"https://en.wikipedia.org/wiki/Sufentanil\" target=\"_blank\">sufentanil</a>&nbsp;(synthetic opioid five to ten times as potent as fentanyl) delivered as often as once per hour sublingually (under the tongue) via a disposable, pre-filled, single-dose applicator.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246654\" data-linked=\"FDA accepts AcelRx&#39;s NDA for pain med ARX-04; action date October 12; shares ahead 7% premarket\" data-tweet=\"$ACRX - FDA accepts AcelRx&#39;s NDA for pain med ARX-04; action date October 12; shares ahead 7% premarket https://seekingalpha.com/news/3246654-fda-accepts-acelrxs-nda-for-pain-med-arxminus-04-action-date-october-12-shares-ahead-7?source=tweet\" data-url=\"https://seekingalpha.com/news/3246654-fda-accepts-acelrxs-nda-for-pain-med-arxminus-04-action-date-october-12-shares-ahead-7\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>12&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246653\" data-ts=\"1488199855\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ITRN\" target=\"_blank\">ITRN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246653-on-ituran-locations-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Ituran Location&#39;s Q4</a></h4><ul>     <li>Ituran Location (NASDAQ:<a href='https://seekingalpha.com/symbol/ITRN' title='Ituran Location and Control Ltd.'>ITRN</a>) reports Location-based services revenue increased 16.1% to $37.27M in <a href=\"https://seekingalpha.com/pr/16753687-ituran-location-control-ltd-presents-results-full-year-and-fourth-quarter-2016\" target=\"_blank\">Q4</a>, primarily due to increase in the subscriber base.</li>     <li>Wireless communications product revenue advanced 11.9% to $13.09M.</li>     <li>Net subscriber +22K in the quarter.</li>     <li>Subscriber base +11.5% Y/Y to 1,057K.</li>     <li>Gross profit rate improved 150 bps to 52.4%.</li>     <li>Operating margin rate expanded 220 bps to 25.8%.</li>     <li>EBITDA margin rate slipped 40 bps to 31.9%.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3246653\" data-linked=\"More on Ituran Location&#39;s Q4\" data-tweet=\"$ITRN - More on Ituran Location&#39;s Q4 https://seekingalpha.com/news/3246653-on-ituran-locations-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3246653-on-ituran-locations-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246647\" data-ts=\"1488198445\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BCRX\" target=\"_blank\">BCRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246647-biocryst-pharmas-next-generation-killikrein-inhibitor-shows-positive-effect-in-mid-stage-hae\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioCryst Pharma&#39;s next-generation killikrein inhibitor shows positive effect in mid-stage HAE study; shares ahead 4% premarket</a></h4><ul><li>BioCryst Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/BCRX' title='BioCryst Pharmaceuticals, Inc.'>BCRX</a>) is up&nbsp;<font color='green'>4%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16753664-biocryst-reports-positive-interim-results-apexminus-1-trial\" target=\"_blank\">announcement </a>of encouraging results in a Phase 2 clinical trial, APeX-1, assessing its next-generation killikrein inhibitor, BCX7353, as a preventative treatment to reduce the frequency of attacks in patients with hereditary angioedema &#40;HAE&#41;.</li><li>An interim analysis was performed on 24 HAE subjects who completed 28 days of treatment (BCX7353 = 11; placebo = 13). The baseline attack rate was ~1/week and average C1 inhibitor levels were less than 20% of the normal mean (severe angioedema).</li><li>The treatment group showed a 63% reduction in attack rate (mean rate = 0.34/week) compared to 0.92/week for placebo (p=0.006). In the intent-to-treat population of 28 subjects, the mean attack rates were 0.44/week and 0.91/week, respectively (p=0.035).</li><li>Daily dosing with BCX7353 inhibited kallikrein throughout the 24-hour dosing interval with the degree of inhibition similar to that observed in healthy subjects in the Phase 1 study (same dose).</li><li>Treatment-emergent adverse events included common cold (n=3/14), diarrhea (n=4/12), flatulence (n=2/14) and fatigue (n=2/14).</li><li>The steady-state drug levels observed far exceeded the proposed therapeutic target range so APeX-1 has been amended to include a 62.5 mg once-daily regimen. The number of subjects in the 125 mg and 250 mg (both once-daily) has been increased to more fully characterize the dose response.</li><li>Management will host a conference call this morning at 9:00 ET to discuss the data.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3202627-biocryst-pharmas-mid-stage-study-next-generation-kallikrein-inhibitor-underway\" target=\"_blank\">BioCryst Pharma's mid-stage study of next-generation kallikrein inhibitor underway</a> (Aug. 11, 2016)</li></ul><div class=\"tiny-share-widget\" data-id=\"3246647\" data-linked=\"BioCryst Pharma&#39;s next-generation killikrein inhibitor shows positive effect in mid-stage HAE study; shares ahead 4% premarket\" data-tweet=\"$BCRX - BioCryst Pharma&#39;s next-generation killikrein inhibitor shows positive effect in mid-stage HAE study; shares ahead 4% premarket https://seekingalpha.com/news/3246647-biocryst-pharmas-next-generation-killikrein-inhibitor-shows-positive-effect-in-mid-stage-hae?source=tweet\" data-url=\"https://seekingalpha.com/news/3246647-biocryst-pharmas-next-generation-killikrein-inhibitor-shows-positive-effect-in-mid-stage-hae\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246645\" data-ts=\"1488198410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/URBN\" target=\"_blank\">URBN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246645-urban-outfitters-in-retreat-after-mkm-partners-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Urban Outfitters in retreat after MKM Partners downgrade</a></h4><ul> <li>MKM Partners lowers Urban Outfitters (NASDAQ:<a href='https://seekingalpha.com/symbol/URBN' title='Urban Outfitters, Inc.'>URBN</a>) to a Sell rating from Neutral on deep concerns over margin trends at the company.</li> <li>Weakness at the Anthropologie brand is called out in particular.</li> <li>The investment firm sets a <a href=\"https://twitter.com/Briefingcom/status/836182904044564481\" target=\"_blank\">price target</a> of $20 on the retailer.</li> <li>Shares of URBN are <font color='red'>down 3.27%</font>&nbsp;in premarket trading to $26.00.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3246645\" data-linked=\"Urban Outfitters in retreat after MKM Partners downgrade\" data-tweet=\"$URBN - Urban Outfitters in retreat after MKM Partners downgrade https://seekingalpha.com/news/3246645-urban-outfitters-in-retreat-after-mkm-partners-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3246645-urban-outfitters-in-retreat-after-mkm-partners-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:26 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3246623\" data-ts=\"1488196212\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ONCS\" target=\"_blank\">ONCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3246623-oncosecs-immunopulse-ilminus-12-fast-trackd-for-melanoma-shares-ahead-19-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OncoSec&#39;s ImmunoPulse IL-12 Fast Track&#39;d for melanoma; shares ahead 19% premarket</a></h4><ul><li>Thinly traded nano cap OncoSec Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/ONCS' title='OncoSec Medical Incorporated'>ONCS</a>) is up&nbsp;<font color='green'>19%</font>&nbsp;premarket on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16753673-oncosec-granted-fda-fast-track-designation-immunopulse-ilminus-12-treatment-metastatic\" target=\"_blank\">announcement </a>that the FDA has granted Fast Track status for ImmunoPulse IL-12 for the treatment of metastatic melanoma following progression on pembrolizumab (Merck's KEYTRUDA) or nivolumab (Bristol-Myers Squibb's Opdivo).</li><li>The Fast Track designation provides for more frequent interactions with the FDA review team and a rolling review of the NDA.</li><li>ImmunoPulse IL-12 delivers a pulsed electric field to cells via a hand-held applicator which temporarily increases the porosity of the cell membranes (electroporation). DNA IL-12 is then delivered to the electroporated cells which triggers each cell to produce and secrete IL-12 protein which then identifies and eliminates cancer cells as part of a natural immune response.</li></ul><div class=\"tiny-share-widget\" data-id=\"3246623\" data-linked=\"OncoSec&#39;s ImmunoPulse IL-12 Fast Track&#39;d for melanoma; shares ahead 19% premarket\" data-tweet=\"$ONCS - OncoSec&#39;s ImmunoPulse IL-12 Fast Track&#39;d for melanoma; shares ahead 19% premarket https://seekingalpha.com/news/3246623-oncosecs-immunopulse-ilminus-12-fast-trackd-for-melanoma-shares-ahead-19-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3246623-oncosecs-immunopulse-ilminus-12-fast-trackd-for-melanoma-shares-ahead-19-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":73,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}